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Abbreviations 
AGREE Appraisal of guidelines for research and evaluation 
cART  Combined antiretroviral therapy 
CXR Chest x-ray 
DAA Direct-acting antivirals 
EEA European Economic Area 
EMCDDA European Monitoring Centre for Drugs and Drug Addiction 
GRADE Grading of recommendations assessment, development and evaluation 
HBV Hepatitis B virus 
HCV Hepatitis C virus 
HIV Human immunodeficiency virus 
IGRA Interferon gamma release assay 
LTBI Latent tuberculosis infection 
MSM Men who have sex with men 
PRISMA Preferred reporting items for systematic reviews and meta-analyses 
PWID People who inject drugs 
STI Sexually transmitted infection 
TasP Treatment as prevention  
TB Tuberculosis 
TST Tuberculin skin test 
UNODC United Nations Office on Drugs and Crime 
WHO World Health Organization 
 
Glossary  
Acceptability The degree to which a given intervention is acceptable to the target population 
in relation to the effect of the intervention 
Accessibility The degree to which a given intervention is accessible to the target population 
(availability of good health services within reasonable reach and when needed)  
Active case finding Interventions aimed at promoting early diagnosis by means of provider-
initiated systematic offer for testing, at entrance and/or during stay (including 
at release) 
Active TB Active tuberculosis (TB) refers to disease that occurs in someone infected with 
Mycobacterium tuberculosis. It is characterised by signs or symptoms of active 
disease, or both, and is distinct from latent TB infection, which occurs without 
signs or symptoms of active disease 
Client-initiated testing Testing which is voluntary and performed as the result of a person’s health-
seeking behaviour, triggered by symptoms development or other reasons (i.e. 
passive case finding) 
Comparative study A study designed to compare two or more groups (e.g. types of testing offers 
or testing timings); a statistical measure is provided for that comparison 
Descriptive study A study concerned with, and designed only to describe, the existing 
distribution of variables, without regard to causal or other hypotheses 
Evidence-based guideline A guideline that is largely based on the scientific literature to generate a 
recommendation; good clinical practices or expert opinions could be used to 
supplement the scientific literature 
Feasibility The degree to which it is feasible to implement an intervention in terms of 
time, money, or other circumstances 
Jail Locally-operated, short-term facilities that hold adults awaiting trial or 
sentencing, or both, and people sentenced mostly to a term of less than one 
year 
LTBI LTBI is a state of persistent immune response to prior-acquired Mycobacterium 
tuberculosis antigens without evidence of clinically manifested active TB 
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Mandatory testing Testing which is offered to all eligible people and cannot be refused 
Opt-in testing Testing which is voluntary and offered to all eligible people, often on the basis 
of identified risk factors; the person chooses whether to have the test  
Opt-out testing Testing modality where all eligible people are informed that the test will be 
performed unless they actively refuse; testing is voluntary.  
People in prison Adults (18 years of age or older) detained in prison for custody, remand or 
awaiting trial. In certain instances, the term may include people visiting 
correctional facilities, intervening in various capacities, or prison staff working 
also in various capacities. This population includes vulnerable groups, e.g. 
MSM, transgender people, PWID, foreign-born people, homeless people, 
people with mental health problems, people with substance misuse problems 
Practice-based guideline A guideline that reflects expert opinion or information derived from good 
clinical practice; some literature references (not systematic) may be included 
Prison All institutions where a state holds adults deprived of their liberty (e.g. prison 
or jail), either sentenced or on pre-trail detention (remand), excluding migrant 
centres, and police detention rooms, and other facilities such as juvenile 
prisons or secure training centres for children and young people. 
Provider-initiated testing Testing which is voluntary and offered to eligible individuals by healthcare 
providers. In this document we use the term ‘provider-initiated’ to describe 
both opt-in and opt-out testing offers. 
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Executive summary 
Compared with the general public, people in prison in the EU/EEA have a higher burden of communicable diseases 
such as human immunodeficiency virus (HIV), hepatitis B, hepatitis C, syphilis, gonorrhoea, chlamydia and 
tuberculosis (TB). Increased disease prevalence in this population is recognised as a significant public health 
concern, both for people living and working in prisons and for the general population at large because the vast 
majority of people held in prisons eventually return to their communities. Yet, incarceration may represent a unique 
opportunity to make adequate healthcare services available to people and target groups that are usually hard to 
reach when in the community. Active case finding is one of the key measures for the prevention and control of 
communicable diseases that should be considered for broader implementation in prison settings. It supports early 
diagnosis, ensures that infected people can receive early treatment and care, and thus contributes to prevent 
onward disease transmission. The successful implementation of evidence-based interventions in prison settings 
requires an in-depth knowledge of structural hurdles, individual barriers, and the characteristics and behaviours of 
the prison population. 
To this aim, the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) have joined forces to develop a common evidence-based guidance for the 
prevention and control of communicable diseases in prison settings in the EU/EEA. This document provides EU/EEA 
Member States with evidence-based scientific advice on active case finding options. These options can be applied 
to the planning and implementation of interventions that promote the early diagnosis of communicable diseases in 
prison settings.  
Scope 
This guidance focuses on high-burden communicable diseases in prison settings. It covers diseases for which 
evidence on active case finding interventions in prison settings could be retrieved though a systematic review of 
the literature, i.e. viral hepatitis (B and C), HIV, sexually transmitted infections (STIs) and TB.  
This guidance focuses on adults aged 18 years or older who are detained in prison for custody, remand, or 
awaiting trial. In certain instances, people visiting correctional facilities or intervening in various capacities, and 
prison staff may be included.  
Target audience 
The target audiences for this guidance are national policymakers, professionals and institutions responsible for the 
planning of healthcare services in the national/subnational custodial system, professionals and entities responsible 
for the planning and provision of healthcare services in prison institutions, civil society organisations, and non-
governmental organisations with an interest in prison health. 
Evidence-based public health guidance 
Research findings relevant to this guidance have been reviewed and assessed using evidence-based medicine 
(EBM) principles adapted to a public health framework. To produce this guidance, scientific evidence from peer-
reviewed and grey literature was assessed. Results were combined with expert advice and considerations on harms 
and benefits, human rights, equity, ethics, and user preferences. Country-specific care models also contributed to 
the development of intervention options for national and subnational public health programmes in European prison 
settings. 
Key conclusions 
ECDC and EMCDDA assessment of active case finding for HBV, HCV 
and HIV 
Based on the available evidence on active case finding for HBV, HCV and HIV in prison settings, and considering 
the high prevalence of infection and the availability of effective prevention and control measures, it is advisable to 
offer testing for HBV, HCV and HIV to all people in prison. 
The available evidence suggests that provider-initiated strategies for viral hepatitis and HIV testing yield a higher 
uptake than client-initiated strategies. However, the body of evidence does not provide clear indications on the 
most effective timing and testing modality for HBV, HCV and HIV active case finding in prison settings.  
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Provider-initiated testing is also consistent with the general principle of disease prevention as it does not delay 
diagnosis and treatment, which, in turn, can prevent further transmission within prison settings and between the 
prison population and the community at large. Several interventions to increase the uptake of testing could be 
considered, although the level of evidence for the effectiveness of any specific ones above any other intervention is 
very low. 
 
 
ECDC and EMCDDA assessment of active case finding for STI 
Available evidence suggests that provider-initiated strategies for STIs testing yield a higher uptake than client-
initiated strategies. Provider-initiated testing is also consistent with the general principle of disease prevention as it 
does not delay diagnosis and treatment, and thus can prevent complications and transmission within the prison 
setting. However, no clear indication on the most effective timing and modality for STIs active case finding in prison 
settings can be derived from the existing evidence. Several approaches may be considered, including risk-based, 
age-based or universal testing for STIs, but evidence of their effectiveness in EU/EEA prison settings is very 
limited.  
 
 
ECDC and EMCDDA assessment on active case finding for TB and LTBI 
Based on available evidence on TB active case finding in prison settings, and taking into account the public health 
implications of TB transmission in closed settings, it is advisable to offer universal provider-initiated testing at 
prison intake. Provider-initiated testing at prison entry is also consistent with the general principle of disease 
prevention, as this does not delay diagnosis and treatment and thus can prevent further transmission within the 
prison setting.  
LTBI provider-initiated testing could also be considered, at least for individuals who are at high risk of disease 
progression, depending on local epidemiology and the availability of resources. 
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1 Introduction 
1.1 Rationale 
More than 10 million people are held in prison worldwide, most are convicted and sentenced but there is also a 
substantial group held in remand prison until trial or sentencing. On 1 September 2015, just above 600 000 people 
were being held in prisons of the European Union (EU)/European Economic Area (EEA). The imprisonment rate 
varied from 21.3 per 100 000 in Liechtenstein followed by 53 per 100 000 in the Netherlands to 277.7 per 100 000 
in Lithuania [3]. The median age of the prison population ranged from 31 years in France to 40 years in Latvia and 
41 years in Liechtenstein, while the average age ranged from 33.8 years in France to 40 years in Italy and 41.3 
years in Liechtenstein. When considering all of Europe, the median length of a prison stay was seven months [3]. 
Compared with the general public, people in prison in the EU/EEA have a higher prevalence of infection with 
human immunodeficiency virus (HIV), hepatitis B, hepatitis C, syphilis, gonorrhoea, chlamydia and tuberculosis 
(TB) [4]. While in detention, individuals, including those who are healthy on entry, are at higher risk of exposure to 
communicable diseases such as TB, HIV and viral hepatitis. They are also at a higher risk to develop substance use 
disorders or mental illnesses than the general population [5-9].  
Most of the of the people in prison in Europe are from poor communities and vulnerable social groups, with an 
increasing proportion of migrants and people with a minority ethnic background; there is, however, substantial 
variation between countries [3,10]. People with drug use disorders form a large part of the imprisoned population. 
A recent study estimates a prevalence of drug use disorders of 30% among men and 51% among women in 
detention [9].  
The increased prevalence of communicable diseases among people in prison can constitute a risk for the health of 
people who live/work in prison settings and for the general population, as the vast majority of people in prison 
eventually return to their communities. There are several risk factors associated with increased transmission rates 
in prison settings, e.g. proximity (aggravated by overcrowding), which is common in some EU/EEA correctional 
facilities; high-risk sexual behaviour; injecting drug use; sharing of injecting equipment; and tattooing and piercing 
[10,12]. Diet and individual hygiene are also important risk factors, at least for TB. In addition, lack of awareness 
of infection status (often combined with substandard healthcare) appear to have substantial implications for public 
health. There are excellent opportunities for primary, secondary and tertiary prevention measures in prison 
settings, provided they are coupled with adequate linkage to care during detention and after release [5,13]. Prison 
settings can be used to reach vulnerable groups of the population and provide adequate care for them. However, 
large heterogeneity exists between EU/EEA prison settings in communicable disease prevention and care, 
particularly with regard to active case finding [14,15].  
The 2010 Madrid Declaration emphasised that health protection in prison settings is an essential part of public 
health and should be based on the principle of equivalence of health for people in prison. Building on the Madrid 
Declaration, several international organisations, such as the United Nations Office on Drugs and Crime (UNODC) 
and the World Health Organization (WHO), published documents highlighting the importance of health protection 
in prison settings [10,16]. A recent briefing on prison conditions in the Member States by the Policy Department on 
Citizens’ Rights and Constitutional Affairs of the European Parliament addresses the issue of healthcare in prison. It 
states that the ‘general principle is that people in prison should enjoy an equivalent standard of care to persons 
outside prisons, yet their needs tend to be greater than those of free persons, as they often lead a marginalised 
life before entry to prison and as imprisonment may put a strain on their mental health and physical well-being’ 
[17]. This underlines the need for up-to-date, evidence-based guidance on prison health. This report is an effort to 
provide such guidance. It is also the first such guidance project for the EU/EEA.  
1.2 Guidance on communicable diseases in prison settings 
In 2015, the European Centre for Disease Prevention and Control (ECDC) launched the project ‘Guidance on 
prevention of infectious diseases in prison settings’.  
ECDC collaborated closely with the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
throughout the development of this evidence-based guidance document. This document also marks the first time 
that ECDC and EMCDDA to develop a common evidence-based guidance for the prevention and control of 
communicable diseases in prison settings in the EU. During a scoping phase, evidence on the burden of 
communicable diseases, preventive measures and costs in prison settings in the EU published between 2000 and 
2014 was assessed, and existing knowledge gaps on prison settings and communicable diseases were identified. 
An evidence mapping tool was developed, and findings were complemented with information from EU/EEA experts 
in order to define thematic areas to be addressed by the guidance document. 
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The overall objective of this project was to develop an evidence-based guidance on prevention, diagnosis and 
control of communicable diseases in prisons and other custodial settings, with a clear focus on the situation in the 
EU/EEA.  
The guidance follows a modular structure: thematic areas are grouped together as guidance modules (Figure 1). In 
addition to active case finding for selected communicable diseases, the project also addresses several thematic 
areas, namely vaccination strategies (including vaccination at prison entry and vaccination in outbreak situations); 
HIV prevention, care and treatment; viral hepatitis prevention, care and treatment; TB prevention, diagnosis, care 
and treatment; and prevention and control of blood-borne viruses among people who inject drugs.  
Figure 1. Schematic representation of the public health guidance modules on communicable diseases 
in prison settings ensuing from the ECDC and EMCDDA joint project 
 
 
The purpose of this guidance is to provide EU/EEA Member States with evidence-based scientific advice on options 
for active case finding when planning and implementing interventions aimed at the early diagnosis of selected 
communicable diseases in prison settings.  
The target audiences for the document are national policymakers, professionals and institutions responsible for the 
planning of healthcare services in national/subnational custodial systems, professionals and entities responsible for 
the planning and provision of healthcare services in prison institutions, civil society organisations, and non-
governmental organisations with an interest in prison health. 
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2 Background 
2.1 Communicable diseases in the prison setting 
Compared with the general public, people in prison in the EU/EEA have a higher burden of communicable 
diseases [4]. Prisons are considered a risk environment, with increased disease prevalence [5]. The prison 
population consists mainly of individuals from a lower socio-economic status and underserved communities. Most 
people in prison have a high risk of acquiring infections already before incarceration, partly due to behavioural and 
structural factors that are associated with increased likelihood of imprisonment [18]. The risk to acquire a 
communicable disease increases further during incarceration because prison settings amplify adverse health 
conditions due to overcrowding, poor infrastructure, and often inadequate access to healthcare services [5,10]. 
The incidence of behaviours associated with an increased risk of contracting and transmitting blood-borne and 
sexually transmitted infections [19] is higher in prison settings. This includes sharing needles for injecting drugs, 
tattooing and piercing with pointed objects, coercive (including violently coercive sex and rape) sexual activity, 
sharing razors, and episodes of violence with wounds and blood mingling.  
When considering subpopulation groups, people who inject drugs (PWID) are a major risk group for HBV, HCV and 
HIV (blood-borne viruses [BBVs]) infection and are overrepresented in prison settings in the EU/EEA. Recent 
studies estimate that well above 70% of PWID had served prison terms at some point in their lives [11,20]. 
Foreign-born people, which constituted approximately 23% of the European prison population in 2015 [3], are also 
considered a group at increased risk for BBVs. In particular, the prevalence of chronic hepatitis B is higher among 
people originating from countries with high HBV endemicity [21], while people originating from sub-Saharan Africa 
and other areas characterised by generalised HIV epidemics are more likely to have a higher prevalence of 
HIV [22]. 
Several factors contribute to the challenge of diagnosing infectious diseases in the prison population: the silent 
nature of many chronic infections, esp. in the early stages; limited health literacy; and reticent health-seeking 
behaviour. The problem is further aggravated by suboptimal access to care in prison settings. Recent 
epidemiological data show that among people with a positive diagnostic test (serological or immunodiagnostic 
screening) in prison, sizeable proportions were unaware of their status: 3.4% of those who were HIV positive were 
unaware of their infection; even higher proportions were reported for HCV (11.6% unaware of infection), HBV 
(52.7%), and latent TB infection (43.7%) [23]. The high percentage of people in prison who are not aware of their 
health status also increases the risk for transmission [24]. Developing an accurate epidemiologic overview of 
infectious diseases in the prison setting is therefore crucial for public health and healthcare planning purposes.  
2.1.1 Viral hepatitis (B and C) 
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are spread through contact with infected body fluids or blood 
products. These viruses can cause both acute and chronic hepatitis infection, ranging in severity from a mild illness 
that lasts only a few weeks to a serious, lifelong illness and death resulting in cirrhosis and predisposing to 
hepatocellular carcinoma (HCC). Most people with acute HBV or HCV infection do not have any symptoms. Those 
who develop chronic infection are often asymptomatic until decades after infection when symptoms develop 
secondary to serious liver damage [10,25,26].  
Effective prevention measures are currently available for both infections, such as condoms and harm reduction 
measures for PWID. A vaccine is currently available only for HBV. With the availability of antiviral treatment that 
can effectively halt disease progression in chronic hepatitis B, including progression to cirrhosis and HCC, and new 
direct acting antivirals (DAAs) for chronic hepatitis C with cure rates above 90% [27,28], elimination of chronic viral 
hepatitis now seems possible.  
In a recent systematic review of EU/EEA literature coordinated by ECDC, representative prevalence estimates for 
HBV and HCV in people in prison were only available for 11 countries. Ireland (HBV prevalence 0.3%), Bulgaria 
(HBV prevalence 25.2%), Hungary (HCV prevalence 4.9%) and Luxembourg (HCV prevalence 86.3%) were at the 
extreme ends of the spectrum. Most of the reported values were higher than in the general population [29]. 
According to a review on the global burden of communicable diseases among people in prison, HBV and HCV 
prevalence in western Europe was estimated at 2.4% (95% CI 1.6–3.3) and 15.5% (12.2–19.1), respectively. 
When considering only PWID in prison, national HCV estimates were largely above 40% [4]. 
In a 2016 ECDC survey on HBV and HCV testing policies and practices in the EU/EEA, the majority of responding 
countries (11 countries [58%]) stated that HBV and HCV testing was offered on the basis of risk factors or medical 
reasons during prison stay; 21% (four countries) said testing was offered at entry. Some countries had different 
testing practices at different correctional facilities. The remaining countries did not offer testing (one country) or 
reported ‘unknown’ [15].  
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2.1.2 HIV 
HIV is a virus that attacks the immune system and causes a lifelong severe illness with a long incubation period. 
The end-stage of the infection, acquired immunodeficiency syndrome (AIDS), results from the destruction of the 
immune system. HIV is transmitted through infected blood, semen, vaginal fluids or breast milk [10,30]. Numerous 
effective preventive measures exist to control HIV transmission, including barrier contraceptives, treatment as 
prevention and, most recently, pre-exposure prophylaxis. Early treatment of HIV infection with antiretroviral 
therapy has been associated with both individual patient clinical benefits and a dramatic decrease in the risk of 
transmission to sexual partners [31-33]. 
Prevalence estimates for HIV among the prison population are reported as part of the Dublin Declaration 
monitoring [14]. In 2016, 15 EU/EEA countries reported estimates ranging from 0.2% to 15.8%, with Estonia, 
Italy, Spain and Latvia reporting a prevalence above 5% [unpublished ECDC report]. According to a recent study 
assessing the global burden of HIV infection among the prison population, HIV prevalence in western Europe is 
estimated at 4.2% (95% CI 2.7–6.1) [4].  
According to the Dublin Declaration monitoring report, governments in 28 EU/EEA countries claim that they 
delivered HIV testing at scale in prison settings in 2014. Twenty-two EU/EEA countries reported that voluntary 
testing is available in all correctional facilities, while six countries reported that voluntary testing is available in 
some or most correctional facilities. No EU/EEA country reported that voluntary testing was not available at all. In 
2016, one country in the region reported mandatory HIV testing in prison settings (Cyprus) [unpublished ECDC 
report] [14]. In 2016, only six EU/EEA countries gave high priority to HIV prevention by targeting prison 
populations [unpublished ECDC report]. 
2.1.3 Sexually transmitted infections 
Most of the common STIs such as chlamydia, gonorrhoea, syphilis, and trichomoniasis are currently curable [34]. 
Prevention measures such as barrier contraceptives and early treatment are effective in controlling STIs 
transmission. Chlamydia is an STI caused by the Chlamydia trachomatis bacterium and is often asymptomatic. It 
can result in complications in women, most frequently pelvic inflammatory disease (PID) and salpingitis, conditions 
that can lead to infertility and extra-uterine pregnancies. [10,35]. Gonorrhoea is caused by infection with the 
Gram-negative bacterium Neisseria gonorrhoeae. Symptoms reflect localised inflammation of infected mucosal 
surfaces in the genital tract, resulting in urethral discharge and dysuria in men and altered vaginal discharge, lower 
abdominal pain and dysuria in women. Among women, complications similar to chlamydia may occur while among 
both genders disseminated gonococcal infection may occur which can be fatal [36]. Syphilis is caused by the 
bacterium Treponema pallidum. After a three-week incubation period on average, clinical symptoms appear: first a 
primary lesion at the site of infection, which may remain unnoticed, followed by skin rashes or mucous membrane 
lesion around the time when the primary lesions is healing or several weeks afterwards (secondary syphilis). If 
untreated and following long periods of latency, tertiary syphilis may appear which can result in severe symptoms 
affecting multiple organ systems and can be fatal [35]. Trichomoniasis is caused by infection with the parasite 
Trichomonas vaginalis and the infection is largely asymptomatic [37]. Other STIs not covered in this document may 
be of relevance in prison settings, such as for example Mycoplasma genitalium. This bacterial infection is often 
asymptomatic, however it can cause significant morbidity in men and women. Specifically, it can cause urethritis in 
both men and women, and cervicitis and pelvic inflammation in women.  
No data were available on the epidemiology of STIs among the incarcerated population in the EU/EEA. There are, 
however, data available on the notification rates for chlamydia, gonorrhoea and syphilis in the general population 
[192]. In a recent systematic review, the prevalence of chlamydia among sexually active young adults in the 
community was estimated at 3.6% [38]. According to the 2016 round of the Dublin Declaration monitoring, 
15 EU/EEA countries offered STI testing and clinical services in prison settings [unpublished ECDC report].  
2.1.4 Tuberculosis 
Tuberculosis (TB) is an infectious disease caused by a group of Mycobacterium species called the Mycobacterium 
tuberculosis complex. Following the initial infection, the bacteria most often lie dormant without evidence of 
clinically manifested symptoms. This state of persistent immune response to prior-acquired Mycobacterium 
tuberculosis antigens is called latent tuberculosis infection (LTBI). Active TB occurs when, at any time following 
primary infection, the bacteria are no longer controlled by the immune system. The resulting disease most 
commonly affects the lungs (known as pulmonary TB) with symptoms of chronic cough, loss of weight, loss of 
appetite, and general malaise [39]. Extrapulmonary TB may occur, but it is usually not contagious. Transmission of 
TB occurs from a person with active infectious pulmonary TB by airborne droplets (produced by coughing, sneezing 
or talking) that are subsequently inhaled by contacts [10,39]. In this document, active TB refers to infectious 
pulmonary TB.  
In 2015, 17 EU/EEA countries reported 647 new and relapse TB cases in prison settings, resulting in a notification 
rate of 158.9 cases per 100 000 people in detention, ranging from zero in Ireland, Luxembourg, Malta, and 
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Slovenia to 748.5 cases per 100 000 people in prison in Latvia. Overall, the relative risk of contracting TB in a 
prison setting compared with the general population was 10.5. TB cases in prison settings accounted for 1.6% of 
all new cases notified. In Latvia, this group accounted for 4.7% of all reported cases [40].  
A survey evaluating TB control in pre-trial detention centres and prisons in the WHO European Region was 
performed in 2004. Among the respondents, 16 countries were part of the EU/EEA [41]. Active case finding for TB 
was performed at entry in 94% of responding EU/EEA countries; in 56% of these countries, active case finding 
took place during detention; no information was available from Portugal. 
2.2 Public health relevance of early diagnosis 
Prevention of communicable disease transmission can be directed at two pathways: 1) preventing transmission of 
disease from infectious individuals to their contacts, and 2) preventing the development of active disease once any 
contacts have become infected (specifically relevant for TB) [10]. Active case finding to promote early diagnosis is 
one of the key prevention measures targeted at the first pathway.  
Active case finding is aimed at detecting contagious diseases, treating them and thus reducing their 
transmission [42]. It can be defined as the systematic identification of people with a disease (regardless of 
symptoms), in a predetermined target group, by using tests, examinations or other procedures that can be applied 
rapidly. Passive case finding, on the other hand, is dependent on a person’s health seeking behaviour and may be 
prompted by the development of symptoms or by self-assessment, e.g. following risk-taking behaviour [10].  
Active case finding is warranted when interventions are available for those testing positive, such as effective 
treatment regimens (e.g. for hepatitis, HIV, STIs and TB [4]) and the prevention of disease transmission, 
particularly active TB through isolation of infectious TB cases. Other measures include vaccination for HBV; 
effective therapy for STI, HIV and, more recently, HCV; use of condoms or sexual abstinence for HIV and STIs; 
needle exchange programmes for hepatitis and HIV; and treatment of those with LTBI to prevent active TB 
disease [5,33,43].  
Active case finding can be offered on a mandatory or voluntary basis. This guidance focuses on voluntary case 
finding, which can be divided into opt-in testing (testing is offered to all, and a person chooses whether to have 
the test) and opt-out testing (a person is informed that the test will be performed unless they actively refuse) [44]. 
Testing can be offered at different points in time in a prison setting, i.e. at prison entry, during imprisonment (for 
instance through yearly testing rounds), or at release from prison. Entry screening and testing during a prison term 
aims at preventing transmission, while testing at release is a key measure to prevent the infection of community 
members by infected people released from prison settings [45]. 
2.3 Human rights in prison settings and prison health  
Several guidance documents define the principles and standards of prison healthcare delivery [10,46-51]. Together 
with the rich international human rights case law, these documents offer a wide variety of tools, helping prison 
healthcare services to deliver their services in line with human rights requirements and based on the principle of 
equivalence of healthcare between prison and community. 
The enjoyment of the highest attainable standard of physical and mental health is an internationally recognised 
fundamental right of every person, i.e. a human right [52,53]. As described in the documents mentioned above, 
people in prison are entitled to the right to health and – subject only to the deprivation of liberty itself and to the 
limitations that are inescapable for its effective enforcement – all other human rights.  
In consideration of the recognition of people in prison as a key population in a variety of policies and strategic 
documents aiming at controlling infectious diseases [54-56], it may be argued that there is an opportunity to move 
from the principle of equivalence of standards and care to an equivalence of objectives and health outcomes 
[57,58]. Success in improving the health of people in prison requires adequate conditions of detention, appropriate 
hygiene and avoidance of overcrowding. Conversely, there is evidence that poor conditions of detention may 
contribute to the dissemination of communicable diseases and add an additional risk of infection; for example, 
increased risk taking practices in prison are often related to drug use, tattooing, and sexual activities [53,59].  
The public health relevance of early diagnosis is reflected in international human rights case law: ‘[…] the spread of 
transmissible diseases should be a major public-health concern, especially in prisons […] it would be desirable if, 
with their consent, [people] could benefit, within a reasonable time after being committed to prison settings, from 
free screening’ for different types of viral hepatitis, HIV and TB [60]. Testing in prison settings can be seen as an 
opportunity to identify communicable diseases in high-risk and underserved groups [5,61].  
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3 Guidance development 
3.1 Systematic review 
A systematic literature review was performed to assess the evidence base around the effectiveness and suitability 
of active case finding in correctional facilities. The best available evidence and scientific knowledge was collected, 
reviewed and appraised in a transparent and systematic way. The review covers peer-reviewed and grey literature 
and follows international standards, such as Cochrane and PRISMA (‘preferred reporting items for systematic 
reviews and meta-analyses’). A predefined list of databases and websites was searched for relevant articles, 
reports, conference abstracts, guidelines or other documents. A call for papers was also used to elicit submission of 
relevant unpublished materials.  
The systematic review was designed to answer the following questions: 
 What are the diseases that should be covered by active case finding? 
 Which types of active case finding methods are effective? 
 Which service models of active case finding are effective? 
 Which types of active case finding methods are cost-effective? 
 Which service models of active case finding are cost-effective? 
 What is the acceptance of active case finding? 
 How can the acceptance of testing for active case finding be improved? 
 Who should be targeted for active case finding, when, and how often? 
Details are available from an ECDC/EMCDDA report entitled ‘Systematic review on active case finding of 
communicable diseases in prison settings’ [62]. 
3.1.1 Evidence synthesis and grading 
The quality and risk of bias of all included studies from the peer-reviewed literature and the quality of the grey 
literature documents were graded as stated in the systematic review report [62]. The level of evidence of peer-
reviewed studies was determined based on the study design and the risk of bias, following GRADE criteria (‘grading 
of recommendations assessment, development and evaluation’). Since significant heterogeneity existed between 
the included studies, the strength of evidence was not assessed beyond individual studies. 
Grey literature documents were included only if they used transparent methods for collecting and compiling data 
and/or provided data sources/references. Relevant conference abstracts/unpublished research reports were 
checked for duplicity with peer-reviewed literature. Relevant guidelines were critically appraised with a selection of 
criteria derived from the AGREE instrument (‘appraisal of guidelines for research and evaluation’) and were 
categorised as either evidence-based guidelines or practice-based guidelines (with the former considered as higher 
quality; see Glossary).  
To structure the evidence, the evidence base from the systematic review was compiled by developing a specific 
summary for hepatitis, HIV, STIs and TB. The evidence was further analysed by: 
 outcomes: uptake, positivity rate, effectiveness (change in number/percentage tested, change 
prevalence/incidence, other), treatment initiation, cost-effectiveness, acceptability, feasibility, accessibility, 
and 
 intervention descriptor/modality: timing (at entry, during imprisonment, at release), offer (mandatory, opt-
in, opt-out, not specified), testing promotion (e.g. education, counselling).  
3.2 Role of the ad hoc scientific panel 
A multi-sectoral ad hoc scientific panel on active case finding interventions was established to contribute to 
evidence gathering, analysis and interpretation.  
The scientific panel members were selected based on their expertise in prison health, prevention and control of 
communicable diseases and their experience in the development of guidance documents. Experts came from a 
variety of constituencies, such as clinical professional associations, public health institutions, national ministries, 
EU-funded initiatives, international agencies, and civil society organisations from various countries, namely the 
Czech Republic, Estonia, France, Germany, Italy, Romania, Spain, Switzerland and the UK (Appendix 1). 
The members of the scientific panel were invited based on their professional and scientific experience and do not 
represent the interests of any commercial body, Member State, or professional body. All panel members signed 
declarations of interest, which were reviewed by ECDC’s compliance officer. None of the members of the panel 
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declared a conflict of interest. The panel was chaired by one of its members, and ECDC and EMCDDA acted as 
secretariat.  
The scientific panel held four teleconferences and one face-to-face meeting. The first teleconference was held in 
November 2015 and discussed the prioritisation of topics, methodology, and evidence gathering. A Delphi process 
to collect panel opinions on human rights aspects and guiding principles for the guidance was performed ahead of 
the face-to-face meeting. The findings of the systematic review and the results of the Delphi process were 
discussed at a panel meeting in Stockholm on 23–25 May 2016 and during three teleconferences later that year. 
Members of the scientific panel provided valuable input and agreed, through a consensus building approach, on 
several evidence-based guidance statements and human rights considerations which were later included in the 
guidance document. During the face-to-face meeting, participants also identified additional peer-reviewed literature 
and grey literature documents with potentially relevant data, which were then assessed for inclusion in the 
systematic review.  
The scientific panel members contributed to the production of this document and, in 2017, reviewed several draft 
versions.  
3.2.1 Development of the guidance statement  
ECDC and EMCDDA developed summary assessments of the evidence base, which are presented in Chapter four 
alongside the conclusions of the scientific panel. The scientific panel members formulated their conclusions based 
on the evidence base (peer-reviewed literature and grey literature), their expert opinion and the following criteria:  
 Prison population subgroup considerations (e.g. migrants, PWID, prison staff) 
 Implementation considerations 
 Equity, ethics and human rights considerations 
 Risks and benefits considerations 
 Supplementary evidence (e.g. evidence derived from community settings) 
 Existing EU/EEA service models for care delivery in prison settings 
For stronger statements, the phrasing ‘it is advisable’ was used; ‘could be considered’ was used for less strong 
statements. 
Considerations for implementation are discussed in Chapter 5, which presents an evidence base heavily indebted to 
expert opinions. 
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4 Conclusions 
This project attempted to identify the most effective and cost-effective approaches for active case finding, with the 
ultimate objective of interrupting communicable disease transmission in prison settings and between prison 
settings and the community, by first testing and then treating infected persons.  
The literature search and review was complemented by expert opinions and insights from country-specific service 
models for each disease/disease group of interest. However, it is important to note that communicable diseases for 
which no evidence base could be compiled are not discussed in this chapter.  
4.1 Viral hepatitis (hepatitis B and C) 
4.1.1 Evidence base 
The evidence base on active case finding for viral hepatitis B and C in prison settings was very weak. For HBV, no 
comparative studies were found; evidence was confined to nine descriptive studies on uptake and positivity rates. 
For HCV, in addition to sixteen descriptive studies on uptake and positivity rates, three comparative studies and five 
cost-effectiveness studies were found. Two of the comparative studies were randomised control trials focussing on 
comparing testing methods rather than offer and timing modalities. Overall, the evidence base was very 
heterogeneous because it was derived from a wide geographical area; publications reported on different testing 
modalities and their combinations, with measures targeted at a range of distinct subpopulations. As a result, it was 
difficult to issue evidence-based conclusions regarding the most effective testing approach for viral hepatitis in 
prison settings. Tables 1 and 2 provide an overview of the evidence base. Further details are presented in the 
ECDC/EMCDDA systematic review [62].  
In addition, three national guidelines [63-65] and one supranational guidelines [10] covering BBV testing in prison 
settings were identified. One guideline recommended performing HBV and HCV testing as part of the assessment 
of newly diagnosed people [10] while the remaining three recommended offering universal testing for HBV and 
HCV to all people entering a prison and again during their detention [63-65]. Further details are presented in the 
ECDC/EMCDDA systematic review [62].  
Table 1. Evidence base on effectiveness of active case finding for HBV and HCV in prison settings  
Intervention 
description 
 how 
 when 
 who 
Studies included  
[no. of studies, design, reference, 
sample size, no. of studies from 
EU/EEA] 
Outcome 1: Uptake Outcome 2: Positivity rate Other outcomes Level of 
evidence 
HBV 
 Provider-
initiated  
 At entry  
 Universal 
N=4 studies; 
1 cross-sectional [66]*, sample size 
[702] 
1 descriptive [61]a, sample size 
[946] 
1 conference abstract [67], sample 
size [711] 
1 unpublished research [68], 
sample size [~2000]  
 
EU/EEA (3) 
>91.3% 0.6%-16.5% NR All very low 
 Provider-
initiated  
 During 
imprisonment  
 Universal 
N=4 studies; 
1 cross-sectional [23]*, sample size 
[3468] 
3 conference abstracts [69-71]*, 
sample size [4072, 2233, 7767]  
 
EU/EEA (4) 
56.3%-83.8% 
 
55% Higher uptake after peer-
education 
 
% tested increased from 10% 
to 42.9% after testing 
promotion initiatives (peer 
educators, leaflets, posters 
and staff training) 
4.4%-13.2% 
 
 
NR All very low 
 Provider-
initiated 
(mandatory) 
 At release  
 Universal 
N=1 study; 
1 cross-sectional [72], sample size 
[916]  
 
EU/EEA (0) 
NR 0.5% NR Very low 
HCV 
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Intervention 
description 
 how 
 when 
 who 
Studies included  
[no. of studies, design, reference, 
sample size, no. of studies from 
EU/EEA] 
Outcome 1: Uptake Outcome 2: Positivity rate Other outcomes Level of 
evidence 
 Provider-
initiated 
 At entry 
 Universal 
N=6 studies; 
1 cross-sectional [66]*, sample size 
[702] 
3 descriptive [61]a,b,c, sample size 
[946, 3034, 1618] 
1 conference abstract [67], sample 
size [711] 
1 unpublished research [73], 
sample size [~2000]  
 
EU/EEA (5) 
9%-91.5% 4.7%-73.5% NR All very low 
 Provider-
initiated  
 At entry 
 High risk (HIV, 
self-reported 
IDU) 
N=1 study; 
Cross-sectional [74], sample size 
[51562]  
 
EU/EEA (0) 
NR 57% Risk-based active 
case finding failed 
to capture 76% of 
predicted HCV 
positives 
Very low 
 Provider-
initiated  
 During 
imprisonment 
 Universal 
N=4 studies; 
2 cross-sectional [23,75]*, sample 
size [3468, 957] 
2 conference abstracts [69,70]*, 
sample size [4072, 2233]  
 
EU/EEA (3) 
26%-83.8% 
 
Higher uptake after peer-
education 
 
% tested increased from 
20.5% to 42.0% after testing 
promotion initiatives (peer 
educators, leaflets, posters 
and staff training) 
10%-32.8% NR All very low 
 Provider-
initiated  
 At entry and 
during 
imprisonment 
 Universal 
N=1 study; 
Cross-sectional [76]*, sample size 
[2716]  
 
EU/EEA (0) 
21.9% 20.5% NR Very low 
 Provider-
initiated 
 NR  
 Universal  
N=1 study; 
1 cross-sectional and qualitative 
[77]*, sample size [30] 
 
EU/EEA (1) 
63.3% 36.8% NR All very low 
 Provider-
initiated  
 At entry 
 High risk  
vs.  
 Client-initiated 
 NR 
 Universal 
N=1 study; 
Before-after [78]*, sample size 
[12297], follow-up [NA] 
 
EU/EEA (0) 
Provider-initiated at entry for 
high-risk: 80.7% 
Provider-initiated at entry 
for high-risk: 25.4% 
 
1.9 cases/month (provider-
initiated at entry, high risk) 
vs. 0.7 cases/month (client-
initiated, universal) 
NR Very low 
 Provider-
initiated 
 At entry 
 Universal  
vs.  
 Routine testing 
(for females 
only) 
 NR 
 Universal 
N=1 study; 
Stepped-wedge cluster RCT [79]*, 
sample size [~3600], follow-up [18 
months] 
(focus on testing method – DBST 
vs. venepuncture)  
 
EU/EEA (1) 
Higher HCV test rates using 
DBST at entry vs. 
venepuncture; insufficient 
evidence of effect of the 
intervention on uptake 
NR NR Low 
 Provider-
initiated 
 NR 
 Universal  
vs.  
 Client-initiated 
 NR 
 Universal 
N=1 study; 
Cluster RCT [80]*, sample size 
[NR], follow-up [6 months] 
(focus on testing method – DBST 
vs. venepuncture)  
 
EU/EEA (1) 
Increase of HCV tested using 
DBST vs. client-initiated 
regular practice 
NR NR Moderate 
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Intervention 
description 
 how 
 when 
 who 
Studies included  
[no. of studies, design, reference, 
sample size, no. of studies from 
EU/EEA] 
Outcome 1: Uptake Outcome 2: Positivity rate Other outcomes Level of 
evidence 
 Provider-
initiated 
(mandatory) 
 At release  
 Universal 
N=1 study; 
Cross-sectional [72], sample size 
[916]  
 
EU/EEA (0) 
NR 1.7% NR Very low 
DBST: dried blood spot testing, HCV: hepatitis C virus, NA: not applicable, NR: not reported, PWID: people who inject drugs, vs.: 
versus 
* Used different promotion strategies: posters and personalised information presentation [66]; direct mail about advantages of 
screening from peer educators and pamphlets on importance of testing [23]; peer educators, leaflets, posters and staff training 
[69]; informational videos, post-testing counselling, appointment reminder card [75]; mandatory education session on hepatitis 
[76]; information sheets about study, no reimbursements/inducements [77]; educational seminar for staff on benefits of 
identifying acute HCV/non-acute HCV [78]; pre- and post-test counselling [79]; staff training on counselling, pre- and post-test 
counselling [80] 
a-c The following articles from the review by Rumble et al. [61] were part of the evidence base: a. Watkins, b. Horne, c. Skipper  
Table 2. Evidence base on cost-effectiveness of active case finding for HBV and HCV in prison settings  
Intervention 
description 
 how 
 when 
 who 
 
Studies included 
[no. of studies, 
perspective, reference, 
time horizon, no. of 
studies from EU/EEA]  
Scenarios Conclusions Level of 
evidence 
 Provider-
initiated  
 At entry 
 High risk  
vs.  
 Client-initiated 
 NR 
 High risk  
N=2 studies [81,82], 
perspective [healthcare 
provider], time horizon 
[30 years, 80 years] 
 
EU/EEA (2), UK (2) 
1. HCV test following a lecture 
(general or IDU-focused) 
 
2. Symptom-based HCV case finding 
In one study on PWID, case-finding at entry 
compared to symptom-based case finding was likely 
cost-effective based on reported ICER below 30 000 
GBP per QALY, with the scenario using an IDU-
focused lecture being the most cost-effective. In the 
other study contradicting results were found, 
whereby testing at entry after a lecture for PWID is 
likely not cost-effective compared to client-initiated 
HCV case finding based on reported ICER. 
All moderate 
 Provider-
initiated 
 NR 
 High risk  
N=1 study [83]; 
perspective [healthcare 
provider], time horizon 
[100 years]  
 
EU/EEA (1), UK (1) 
1. DBST for HCV 
 
2. Venepuncture for HCV 
Among PWID, DBST is likely not cost-effective 
under UK commonly used willingness-to-pay 
thresholds of GBP 30 000.  
Moderate 
 Provider-
initiated  
 At entry 
 Universal or 
after verbal 
screening 
vs.  
 No active case 
finding 
N=1 study [84]; 
perspective [healthcare 
provider], time horizon 
[NR]  
 
EU/EEA (1), UK (1) 
1. No active case finding 
 
2. Verbally screening for past positive 
HCV test and ever having injected 
illicit drugs, or only one of each 
 
3. No verbal screening (lecture only) 
The incremental cost-effectiveness analysis 
revealed that verbally screening for past positive 
HCV test and ever having injected illicit drugs prior 
to opt-in HCV testing at entry is the most cost-
effective option. 
Low 
 Provider-
initiated  
 One-time and at 
entry  
 High-risk or 
universal 
vs.  
 No active case 
finding 
N=1 study [85]; 
perspective [societal], 
time horizon [30 years]  
 
EU/EEA (0), USA (1) 
1. No active case finding  
 
2. HCV active case finding of 
active/former currently incarcerated 
PWIDs and active/former PWIDs at 
entry for up to 1 year  
 
3. HCV active case finding of all 
currently incarcerated persons and all 
entrants for up to 1, 5 or 10 years 
The authors concluded that universal opt-out active 
case finding in prison for HCV is highly cost-
effective (ICER below 50 000 USD per QALY) for at 
least 10 years. Scenarios for former and current 
PWID were also assessed.  
Moderate 
DBST: dried blood spot testing, HCV: hepatitis C virus, IDU: injecting drug use, NHS: National Health Service, NR: not reported, 
PWID: people who inject drugs, vs.: versus 
4.1.2 Ad hoc scientific panel opinion 
As reflected by the high positivity rate of chronic HBV and HCV infections reported by the included studies 
(Table 1), the prevalence of viral hepatitis in prison settings – and in particular of HCV – is considerably higher than 
in the general population [4,86]. The transmission risk for HBV and HCV is increased in prison settings due to a 
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combination of structural and behavioural risk factors. There is also a higher proportion of severe clinical outcomes 
due to a higher prevalence of co-infection with HBV/HCV or HIV [4,10,29].  
Despite the low level of evidence and the lack of conclusive studies on active case finding modalities in prison 
settings, the scientific panel shared the opinion that it is advisable to actively promote HBV and HCV testing in 
order to offer appropriate and timely interventions, such as vaccination and treatment, and thus reduce the risk of 
further disease transmission. 
Since chronic viral hepatitis may remain asymptomatic for many years, a large proportion of infected individuals 
may be unaware of their status. Reducing the number of undiagnosed cases is a major global priority and a key 
requirement to attain the WHO goal of viral hepatitis elimination [87]. Within this framework, the scientific panel 
evaluated targeted testing of subgroups with a high risk, such as former/current PWID or people from endemic 
countries, based on studies on selective testing [78,81-84]. Panel members expressed concerns about risk 
assessment approaches, especially their difficult implementation, potential discrimination, and inadequate 
sensitivity. The panel considered universal testing approaches aimed at all individuals in a prison setting as 
advisable, based on findings from more recent studies [74,85], existing recommendations from national guidelines, 
and evidence of their impact [2,88]. 
While the panel agreed that active case finding for viral hepatitis should offer adequate confidentiality, counselling, 
and linkage to care, it also pointed out the opportunities offered by post-test prevention and control measures, 
such as HBV vaccination for unvaccinated HBV-negative individuals and effective therapy for chronic viral hepatitis. 
Effective treatment is available for those identified as chronically infected with HBV; it can halt disease progression, 
including deterioration to cirrhosis and hepatocellular carcinoma [28]. For HCV, the increasing availability of the 
highly effective DAAs that can cure HCV [27] and the mounting evidence on the extensive benefits of expanding 
DAA treatment in prison settings for the individual as well as the community at large [85,89,90], provide an 
additional and compelling argument for promoting active case finding. Provision of treatment, at least for HCV is a 
valid component of viral hepatitis prevention, both in prison settings and in the community [89].  
Although it was not possible to agree on the ideal timing and modality of testing for viral hepatitis in prison settings 
based on available evidence, the panel reached consensus on active case finding for hepatitis B and C, provided 
that the 7C principles1 are guaranteed. It was considered beneficial to offer universal provider-initiated HCV and 
HBV testing at, or near, prison entry, followed by appropriate linkage to care in order to reduce the risk of 
transmission within prison settings (very low level of evidence). However, since transmission may still occur within 
the prison setting, for example through unsafe sex and sharing of needles/syringes and other paraphernalia (e.g. 
needles for tattooing), it is also advisable to offer provider-initiated testing to high-risk groups, such as imprisoned 
MSM and PWID, at regular intervals or after an exposure incident (very low level of evidence). Client-initiated 
testing was considered a valid approach to complement and enhance these efforts and thus could be continuously 
promoted during incarceration (very low level of evidence). 
ECDC and EMCDDA assessment 
Based on the available evidence on active case finding for HBV and HCV in prison settings, and considering the 
high prevalence of infection and the availability of effective prevention and control measures, it is advisable to offer 
testing for HBV and HCV to all people in prison. 
The available evidence suggests that provider-initiated strategies for viral hepatitis testing yield a higher uptake 
than client-initiated strategies. However, the body of evidence does not provide clear indications on the most 
effective timing and testing modality for HBV and HCV active case finding in prison settings.  
Provider-initiated testing is also consistent with the general principle of disease prevention as it does not delay 
diagnosis and treatment, which, in turn, can prevent further transmission within prison settings and between the 
prison population and the community at large. Several interventions to increase the uptake of testing could be 
considered, although the level of evidence for the effectiveness of any specific ones above any other intervention is 
very low. 
 
 
                                                                    
1 7Cs principles: consent, confidentiality, counselling or communication, correct test results, connection to care and treatment, 
supportive culture of the prison system, and continuity of care post-release. See Chapter 5 for an explanation of these principles. 
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4.2 HIV 
4.2.1 Evidence base 
The evidence base on active case finding for HIV in prison settings was composed of 37 descriptive studies 
reporting on uptake, positivity rates and, to a lesser extent, on treatment initiation. Seven comparative studies and 
one relevant cost-effectiveness study were also retrieved. The evidence base was derived from a broad 
geographical area; it reported on different testing modalities and their combinations, with interventions targeted at 
a range of distinct subpopulations. Overall, the evidence base was of low/very low quality. As a result, it was 
difficult to develop evidence-based conclusions regarding the most effective testing approach for HIV in prison 
settings. Tables 3 and 4 provide an overview of the evidence base. Further details are presented in the 
ECDC/EMCDDA systematic review [62]. 
Table 3. Evidence base on effectiveness of active case finding for HIV in prison settings  
Intervention 
description 
 how 
 when 
 who 
 
Studies included  
[no. of studies, design, reference, 
sample size, no. of studies from 
EU/EEA] 
Outcome 1: Uptake Outcome 2: Positivity 
rate 
Other outcomes Level of 
evidence 
 Provider-
initiated  
 At entry 
 Universal 
N=18 studies; 
10 cross-sectional [61,91-
95]*,a,b,c,d,e, sample size [680, 2791, 
~1700, 977, 100, 9405, 550000, 
NR, 30799, NR] 
5 descriptive [61]f,g,h,I,j, sample size 
[946, 39073, 140739, NR, 129084] 
2 prospective controlled trials [61]k,l, 
sample size [323, 298], follow-up 
[NR] 
1 conference abstract [67], sample 
size [711] 
 
EU/EEA (1) 
6%-98% 0%-5.4% 99.9-100% of HIV 
positives received their 
test results 
 
Opt-in strategy failed to 
detect 28%-91% of HIV 
cases 
 
Acceptance increased 
from 43% with opt-in to 
64% with opt-out 
All very low 
 Provider-
initiated  
 At entry and 
during 
imprisonment 
(at regular 
intervals)  
 Universal 
N=1 study; 
Cross-sectional [96]*, sample size 
[3289] 
 
EU/EEA (1) 
97.3% at entry; 96% during 
imprisonment 
12.5% at entry; 0.06% 
during imprisonment 
NR Very low 
 Provider-
initiated  
 At entry or 
during 
imprisonment 
 Universal 
N=8 studies; 
1 comparative (focusing on testing 
method – blood vs. oral) [97]*, 
sample size [1314], follow-up [NA] 
2 cross-sectional [76,98]*, sample 
size [NR, 2716] 
5 conference abstracts [69,70,99-
101], sample size [4072, 2233, 
19772, 1410, 6691] 
 
EU/EEA (5) 
24.6%-83.8% 
 
63% increase in testing 
uptake when blood or oral 
testing offer instead of 
blood only 
 
42% increase in testing 
uptake testing promotion 
initiatives (peer educators, 
leaflets, posters and staff 
training) 
0.8%-17% Treatment initiation: 
59.1% 
All very low 
 Provider-
initiated  
 NR 
 Universal 
N=4 studies; 
1 cluster-randomised trial (focusing 
on promotion intervention) [102], 
sample size [3300], follow-up [NR] 
1 longitudinal (focusing on 
promotion intervention) [103], 
sample size [3096], follow-up [12 & 
18 months] 
2 conference abstracts [104,105], 
sample size [10857, 320] 
 
EU/EEA (2) 
82.5% 
 
Testing uptake was 48-53% 
after staff received HIV 
service training and 
coaching vs. 49-44% where 
staff only receiving the HIV 
service training. OR=0.16 
(not significant) 
 
Significant increase in 
uptake of testing after peer 
education program vs. no 
intervention (at 12 months: 
OR=2.76; at 18 months: 
OR=1.78) 
9.9%-26.5% Treatment initiation: 78% 
 
 
 
 
 
 
 
 
 
 
 
 
Significantly more 
attendees indicated they 
planned to schedule an 
HIV test after peer-
education 
Moderate-low 
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Intervention 
description 
 how 
 when 
 who 
 
Studies included  
[no. of studies, design, reference, 
sample size, no. of studies from 
EU/EEA] 
Outcome 1: Uptake Outcome 2: Positivity 
rate 
Other outcomes Level of 
evidence 
 Provider-
initiated 
 At entry and 
release 
 Universal 
N=1 study; 
Cross-sectional [66]*, sample size 
[702] 
 
EU/EEA (1) 
91.3% at entry; 4.2% on 
release 
0.3% at entry; 0% on 
release 
NR Very low 
 Provider-
initiated 
 During 
imprisonment 
 Universal 
N=1 study; 
Cross-sectional [23]*, sample size 
[3468] 
 
EU/EEA (1) 
67.4% 3.8% NR Very low 
 Provider-
initiated  
 At entry  
 Universal 
vs. 
 Client-initiated 
 At entry 
 Universal 
 Universal 
N=2 studies; 
Descriptive (comparing different 
offer types) [61]m, sample size [opt-
in 16908, opt-out 5168] 
Before-after [61]n, sample size 
[2886], follow-up [NA] 
 
EU/EEA (0) 
Increase from 5% (testing 
on request) to 72% (opt-in) 
to 90% (opt-out) 
 
Increased from 18% (client-
initiated) to 73% (provider-
initiated) 
0.1% new (opt-in and opt-
out)  
 
0.3% (provider-initiated) 
100% HIV positives 
received results 
All very low 
 Provider-
initiated  
 At release 
 Universal 
N=1 study; 
Cross-sectional [106]*, sample size 
[507] 
 
EU/EEA (0) 
60% 0.3% 100% received test 
results 
Very low 
 Provider-
initiated  
 At entry  
 Universal 
vs. 
 Client-initiated 
 During 
imprisonment 
 Universal 
N=2 studies; 
Cross-sectional [44], sample size 
[54664] 
Surveillance [107], sample size 
[22338] 
 
EU/EEA (0) 
34-39% provider-initiated at 
entry; 6% client-initiated 
during imprisonment 
3.3% provider-initiated at 
entry; 12% client initiated 
during imprisonment 
NR All very low 
 Provider-
initiated 
 At entry and 
during 
imprisonment 
 High risk 
(PWID) 
N=1 study; 
Conference abstract [108], sample 
size [144] 
 
EU/EEA (1) 
NR 35.4% Treatment initiation: 
35.2% 
 
 Provider-
initiated 
 NR 
 Universal 
N=2 studies; 
2 Surveillance [109,110], sample 
size [NR, NR] 
 
EU/EEA (0) 
Increased by 194% from 
1992 to 1998 
 
Increased from 2009 to 
2012 and decreased slightly 
in 2013, estimated annual 
percent change of 2.7% 
3.4% of tests were HIV-
positive. The percentage 
of all tests that were HIV-
positive decreased nearly 
50% from 1992 to 1998 
 
From 2009 to 2013, HIV-
positive cases increased 
significantly with an 
annual percent change of 
4.4% 
Treatment initiation: The 
percentage of HIV-
positive people in 
detention linked to 
medical care significantly 
increased by 27% 
between 2009 and 2013 
All very low 
 Provider-
initiated 
(mandatory) 
 At release  
 Universal 
N=1 study; 
Cross-sectional [72], sample size 
[916] 
 
EU/EEA (0) 
NR 0.1% NR Very low 
HIV: human immunodeficiency virus, NA: not applicable, NR: not reported, OR: odds ratio, PWID: people who inject drugs, vs.: 
versus 
* Used different promotion strategies: pre-and post-test counselling [Spaulding]; group-based HIV education while waiting for 
test results, post-test counselling [95]; advertising for rapid HIV tests, pre-test counselling, active follow-up and referral for 
positive testers [92]; counselling and active referral of positives [93]; counselling [96]; pre-test HIV counselling [97]; mandatory 
HIV education session before decision on whether to take test [76]; disease education, post-test counselling [98]; peer educators 
and infectious disease specialists [69]; posters, personalised information letters [66]; presentation on advantages of testing by 
peer educators, pamphlets on importance of testing [23]; educational materials, pre- and post-counselling, active referral of 
positive testers to community-based care [106]; presentation on BBV [44]; counselling [107]; modified process improvement 
model (staff receive HIV service training and are taught about the model; staff only receive HIV service training) [102]; peer 
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educator (fellow prisoner) and student (fellow prisoner)or peer-education programme (intensive training for peer educators, 
ongoing HIV education sessions given by peer educators to people in detention [103] 
a-n The following articles from the review by Rumble et al. [61] were part of the evidence base: a. Cotton-Oldenberg, b. Behrendt, 
c. Hoxie, d. Andrus, e. Beckwith 2007, f. Watkins, g. Spaulding, h. Beckwith 2010, i. Beckwith 2011, j. Beckwith 2012, k. Kavasery 
2009a, l. Kavasery 2009b, m. Strick, n. Liddicoat 
Table 4. Evidence base on cost-effectiveness of active case finding for HIV in prison settings  
Intervention 
description 
 how 
 when 
 who 
 
Studies included 
[no. of studies, 
perspective, reference, 
time horizon, no. of 
studies from EU/EEA]  
Scenarios Conclusions Level of 
evidence 
 Provider-
initiated 
 At or near 
release 
 Universal 
vs.  
 No active case 
finding 
N=1 study [111], 
perspective [societal], 
time horizon [NR] 
 
EU/EEA (0), USA (1) 
1. HIV active case finding 
 
2. No active case finding 
Offering HIV counselling and testing to 10 000 
people held in prison resulted in 50 new or 
previously undiagnosed infections and averts four 
future cases at a cost of USD 125 000 to prison 
systems while saving to society over USD 550 000. 
Low 
HIV: human immunodeficiency virus, NR: not reported, vs.: versus 
Additionally, three national guidelines [88,112,113] and two supranational guidelines [10,16] covering HIV testing in prison 
settings were identified. National guidelines from the United Kingdom recommended provider-initiated testing at entry [88,112] 
and during imprisonment [88], with annual HIV testing for MSM [113]. A WHO document recommended provider-initiated testing 
during medical examinations to all people in detention unless an HIV test was taken within the previous 12-month [10]. 
Conversely, UNODC supports client-initiated testing and counselling on request [47]. In two additional guidelines, which are not 
specific to prison settings, it is recommended that HIV tests should be offered routinely [54] or annually [114] to all people from 
key populations. Further details are presented in the ECDC/EMCDDA systematic review [62].  
4.2.2 Ad hoc scientific panel opinion 
The evidence base confirmed previous indications [4,115] of a higher prevalence of HIV in the EU/EEA prison 
population than in the general population. There are, however, variations across studies and geographical areas 
(Table 3). UNAIDS and WHO call for global action to reduce undiagnosed HIV cases so that 90% of all people living 
with HIV know their HIV status [116]. These considerations alongside the notion of a heightened HIV transmission 
risk due to structural and behavioural factors [4,10], provide a strong argument for scaling-up testing in prison 
settings. Despite the overall low level of evidence, the scientific panel agreed that it is advisable to actively 
promote HIV case finding in prison settings in order to offer appropriate and timely treatment and thus reduce the 
risk of onward transmission. 
The scientific panel agreed that active case finding for HIV should be provided in the context of adequate 
confidentiality, counselling and linkage to care. Early diagnosis coupled with prompt linkage to care are essential to 
ensure individual benefits from early antiretroviral treatment [32]. In addition, treatment also prevents sexual 
transmission of HIV [117].  
The ad hoc scientific panel could not conclude, based on the available evidence, on the ideal timing and modality 
of testing for HIV in prison settings. The panel reached a consensus on active case finding for HIV, provided that 
seven principles (7Cs)2 are guaranteed. It was considered beneficial to offer universal provider-initiated HIV testing 
at entry to reduce the risk of transmission within prison settings (very low level of evidence), despite the lack of 
evidence on economic implications. It is also advisable to offer provider-initiated testing to high-risk groups, such 
as MSM and PWID, at regular intervals or after an exposure incident (very low level of evidence). Client-initiated 
testing was considered a valid approach to complement and enhance these efforts; client-initiated testing could 
also be continuously promoted during incarceration (very low level of evidence). 
ECDC and EMCDDA assessment 
Based on the available evidence on active case finding for HIV in prison settings, and taking into account the high 
prevalence of infection and the availability of effective prevention and control measures, it is advisable to offer 
testing for HIV to all people in prison. 
 
                                                                    
2 The seven principles (7Cs) are: consent, confidentiality, counselling or communication, correct test results, connection to care 
and treatment, supportive culture of the prison system, and continuity of care post-release. See Chapter 5 for an explanation of 
these principles. 
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The available evidence suggests that provider-initiated strategies for HIV testing yield a higher uptake than client-
initiated strategies. However, the body of evidence does not provide clear indications on the most effective timing 
and testing modality for HIV active case finding in prison settings.  
Provider-initiated testing is also consistent with the general principle of disease prevention, as it does not delay 
diagnosis and treatment, which, in turn, can prevent further transmission within prison settings and between the 
prison population and the community at large. Several interventions to increase the uptake of testing could be 
considered, although the level of evidence for the effectiveness of any specific ones above any other intervention is 
very low (see Sections 5.1.3 and 5.1.6). 
 
4.3 Sexually transmitted infections 
4.3.1 Evidence base 
The evidence base on active case finding for STIs in prison settings was composed of 25 relevant publications, 15 
of which reported on chlamydia and gonorrhoea, eight on syphilis and two on trichomoniasis. Seven studies on 
chlamydia and gonorrhoea were descriptive, five were comparative, and three were cost-effectiveness studies. 
Seven studies on syphilis were descriptive; one was a cost-effectiveness study. One study on trichomoniasis was 
descriptive and one was comparative. Descriptive studies reported mostly on uptake, positivity rates and treatment 
initiation. The evidence base derived largely from outside the EU/EEA, posing concerns over its applicability to 
EU/EEA prison settings. In addition, the included studies reported on different testing modalities and testing 
combinations and were targeted at a range of distinct subpopulations. Overall, the evidence base was very limited 
and of low/very low quality. As a result, it was challenging to develop evidence-based conclusions regarding the 
most effective testing approach for STIs in prison settings. Tables 5 and 6 provide an overview of the evidence 
base. Further details are presented in the ECDC/EMCDDA systematic review [62]. 
Table 5. Evidence base on effectiveness of active case finding for STIs in prison settings  
Intervention 
description 
 how 
 when 
 who 
Studies included 
[no. of studies, design, reference, 
sample size, no. of studies from 
EU/EEA]  
Outcome 1: Uptake Outcome 2: Positivity 
rate 
Other outcomes Level of 
evidence 
Chlamydia and gonorrhoea 
 Provider-
initiated  
 At entry 
 Universal 
N=2 studies; 
2 cross-sectional [98,118]*, sample 
size [NR, NR] 
 
EU/EEA (0) 
85.1%-100% CT 6.5%; NG 3.1% Treatment initiation: 
61%-85% (1 study); CT 
79%; NG 66% (1 study) 
All very low 
 Provider-
initiated  
 During 
imprisonment 
 Universal 
N=3 studies; 
1 case-control [119]*, sample size 
[NR], follow-up [NA] 
1 survey (focusing on urine vs. 
vaginal swabs) [120], sample size 
[800] 
1 conference abstract [121], sample 
size [430] 
 
EU/EEA (1) 
82.1%, of which: 97% both 
specimens, 1.5% swab, 
1.9% urine 
CT 5.3%-11%; NG 0.8% NR Low-very low 
 Provider-
initiated 
 At release 
 Universal 
N=1 study; 
Cross-sectional [72]*, sample size 
[916] 
 
EU/EEA (0) 
37.6% CT 0.6%; NG 0% NR Very low 
 Provider-
initiated 
 During 
imprisonment 
 <25 years old 
N=1 study; 
Conference abstract [122], sample 
size [430] 
 
EU/EEA (1) 
98.4% CT 6%; NG 0.2% NR NA 
Public health guidance on active case finding of communicable diseases in prison settings  SCIENTIFIC ADVICE 
18 
Intervention 
description 
 how 
 when 
 who 
Studies included 
[no. of studies, design, reference, 
sample size, no. of studies from 
EU/EEA]  
Outcome 1: Uptake Outcome 2: Positivity 
rate 
Other outcomes Level of 
evidence 
 Provider-
initiated  
 During 
imprisonment 
 Universal 
vs.  
 Provider-
initiated  
 At entry 
 Universal 
N=1 study; 
Cross-sectional [123]*, sample size 
[NR] 
 
EU/EEA (0) 
NR Opt-in during 
imprisonment: CT 5.6%; 
NG 0.9% 
Opt-out at entry: CT 
9.7%; NG 1.3% 
 
Significantly more CT 
positives through opt-out 
at entry 
NR Low 
 Provider-
initiated  
 At entry 
 Universal 
vs.  
 Client-initiated  
 During 
imprisonment 
 Universal 
N=3 studies; 
1 cross-sectional [124]*, sample 
size [2417] 
2 before-after [125,126], sample 
size [NR, 17065], follow-up [NA] 
 
EU/EEA (0) 
At entry: 78.1%-100% 
 
Mean tests per month: 155 
client-initiated vs. 455 
provider-initiated 
At entry: CT 6.4%-7.6%; 
NG 0.9%-2.5% 
 
Mean diagnoses per 
month: 9.3 client-initiated 
vs. 40.8 provider-initiated  
 
86.8% of positives would 
have been missed 
through client-initiated 
testing  
Decrease after 
discontinuation provider-
initiated program: CT 
82.3%, NG 70.9%  
Treatment initiation: 
63%-69.6%  
Low-very low 
 Provider-
initiated  
 At entry 
 ≤35 
vs.  
 Client-initiated  
 During 
imprisonment 
 Universal 
N=1 study; 
Before-after [127], sample size 
[NR], follow-up [NA] 
 
EU/EEA (0) 
NR Change after introduction 
provider-initiated program 
in jail: CT 1636% 
increase in jail, 59% 
increase in community; 
NG 885% increase in jail, 
4% increase in 
community 
NR Very low 
Syphilis 
 Provider-
initiated 
 At entry 
 Universal 
N=5 studies; 
4 cross-sectional [98,128-130]*, 
sample size [NR, 12685, 50941, 
26829] 
1 conference abstract [67], sample 
size [711] 
 
EU/EEA (1) 
69%-91.5% 1.4%- 6% Treatment initiation: 
56.7%-83.5% 
All very low 
 Provider-
initiated 
 During 
imprisonment 
 Universal 
N=2 studies; 
1 cross-sectional [23], sample size 
[3468] 
1 conference abstract [69], sample 
size [4072] 
 
EU/EEA (2) 
55.7%- 56.3% 
 
Uptake improved by 45.7% 
with peer education 
2.1%-2.3% NR Very low 
 Provider-
initiated 
Mandatory 
 At release 
 Universal 
N=1 study; 
Cross-sectional [72]*, sample size 
[916] 
 
EU/EEA (0) 
NR 0.1% NR Very low 
Trichomoniasis 
 Provider-
initiated  
 At entry 
 Universal 
vs.  
 Client-initiated  
 At entry 
 Universal 
N=1 study; 
Before-after [131], sample size 
[833], follow-up [NA] 
 
EU/EEA (0) 
NR 44% (provider-initiated); 
14% (client-initiated) 
NR Very low 
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Intervention 
description 
 how 
 when 
 who 
Studies included 
[no. of studies, design, reference, 
sample size, no. of studies from 
EU/EEA]  
Outcome 1: Uptake Outcome 2: Positivity 
rate 
Other outcomes Level of 
evidence 
 Provider-
initiated  
 At release 
 Universal 
N=1 study; 
Cross-sectional [72]*, sample size 
[916] 
 
EU/EEA (0) 
37.6% 5.5% NR Very low 
CT: Chlamydia trachomatis, NA: not applicable, NG: Neisseria gonorrhoeae, NR: not reported, vs.: versus 
* Used different promotion strategies: active referral for treatment when released before knowing results [118]; disease 
education, post-test counselling [98]; education on STIs before decision on whether to take test, post-test counselling [119]; 
letter describing STD testing process [72]; education on STIs [123]; STI clinic brochures, instructions to follow-up at clinic, direct 
mail on aftercare services [124]; presentation on advantages of testing by peer educators, pamphlets on importance of 
testing [23] 
Table 6. Evidence base on cost-effectiveness of active case finding for STIs in prison settings  
Intervention 
description 
 how 
 when 
 who 
Studies included 
[no. of studies, 
perspective, reference, 
time horizon, no. of 
studies from EU/EEA]  
Scenarios Conclusions Level of 
evidence 
Chlamydia and gonorrhoea 
 Provider-
initiated  
 At entry 
 <30 
vs. 
 Provider-
initiated  
 At entry 
 Universal 
N=1 study [132], 
perspective [healthcare 
and prison services], time 
horizon [NR] 
 
EU/EEA (0), USA (1) 
1. Universal testing at prison entry  
 
2. Age-based testing at prison entry 
<25 or 30 years; client-initiated 
testing for those ≥25 or ≥30 years 
 
3. Client-initiated testing only 
An age-based active case finding program for men 
<30 years of age for CT and NG is nearly as 
effective as universal active case finding (47.7 vs 
49.9 cases treated respectively) and is substantially 
less costly than universal active case finding based 
on incremental cost per case treated (429USD vs 
6,095 USD respectively), from the prison 
perspective. Similar findings were obtained when 
using the healthcare services perspective.  
Low 
 Provider-
initiated  
 At entry 
 ≤35 
vs. 
 No active case 
finding 
  
N=1 study [133], 
perspective [healthcare 
and prison services], time 
horizon [NR] 
 
EU/EEA (0), USA (1) 
1. Universal testing for people in 
detention 8-14 days after entry or 2-3 
days after entry 
 
2. Age-based testing for people in 
detention ≤35 years 8-14 days after 
entry or 2-3 days after entry 
 
3. Client-initiated testing only 
Considering a hypothetical cohort of 100 000 male 
in detention, active case finding for men ≤35 years 
of age for CT and NG was nearly as effective as 
universal testing (995 vs 1099 infections averted 
respectively). Based on incremental cost per 
infection averted, has the least cost compared with 
symptom-based testing, from the perspective of 
correctional health services and the county 
department of public health. 
Low 
 Provider-
initiated  
 At entry 
 Universal 
vs. 
 No active case 
finding 
N=1 study [134], 
perspective [healthcare 
services], time horizon 
[NR] 
 
EU/EEA (0), USA (1) 
1. Universal testing for CT and NG at 
entry 
 
2. Universal testing for CT only at 
entry 
 
3. Client-initiated testing only 
Considering a hypothetical cohort of 10 000 male in 
detention and based on incremental cost per case 
averted, universal active case finding for CT at entry 
only is cost-saving for female detainees, while for 
males this is less clear, compared to universal 
testing for chlamydia and gonorrhoea combined o r 
to client-initiated testing. 
Low 
CT: Chlamydia trachomatis, NG: Neisseria gonorrhoea, NR: not reported, vs.: versus 
In addition to the above, one supranational guideline reporting on testing for STIs in prison settings was identified. The document 
recommended offering voluntary testing for STIs (chlamydia, gonorrhoea and syphilis) to all people in prison with high risk 
behaviours [10]. Other European guidelines not specific for prison settings recommend, over and above symptom-based testing, 
risk-based and age-based approaches for STI testing in the general population [36,135,136]. US guidelines recommend to offer 
universal testing for chlamydia and gonorrhoea to young adults at prison entry and universal testing for syphilis, based on local 
underlying prevalence [137]. Further details are presented in the ECDC/EMCDDA systematic review [62].  
4.3.2 Ad hoc scientific panel opinion 
Despite the overall low level of evidence, the scientific panel shared the opinion that it is advisable to actively 
promote STIs case finding in order to offer appropriate and timely treatment and thus reduce the risk of 
complications and disease transmission. While limited evidence was available on prevalence of STIs among people 
in detention in the EU/EEA, studies from the US reported high prevalence, particularly among young adults in 
prison (Table 5 and 6). STIs transmission within prison settings may be increased by high risk behaviours such as 
sex between men and coercive sexual intercourses. Sex is often regarded as taboo in prison settings and is either 
tolerated or illegal in a number of EU/EEA countries [4,10]. Some groups at high risk for STIs may be 
overrepresented in prison settings, such as male and female sex workers and persons who engage in transactional 
sex. Moreover, the limited coverage of, and access to, preventive measures such as condoms and health promotion 
activities in prison settings in several EU/EEA countries may further increase the risk of disease transmission [115]. 
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In addition to the high risk of transmission and high prevalence in prison populations, some STI increase the risk of 
acquisition of HIV, which supports the rationale for early diagnosis and treatment.  
STIs often go unnoticed, and although symptom-driven testing is the most commonly implemented approach, it 
may be insufficient [124-127,131]. Effective and short-course treatment options are available and existing evidence 
suggest post-diagnosis treatment uptake is satisfactory (Table 5). Together with the evidence of increased uptake 
and positivity rate following the introduction of provider-initiated testing compared with client-initiated (or 
symptom-based) approaches, these arguments support the implementation of active case finding initiatives in 
prison settings. Limited evidence exists on identifying target populations for active case finding initiatives; different 
approaches are considered, e.g. age-based or risk-based testing for chlamydia, gonorrhoea or trichomoniasis, and 
risk-based or universal testing for syphilis.  
Although it was not possible to agree on the ideal timing and modality of testing for STIs in prison settings based 
on the available evidence, the scientific panel reached a consensus on active case finding for STIs, provided that 
the 7C principles3 are guaranteed. It was considered beneficial to assess the risk for STIs at prison entry, and 
subsequently offer provider-initiated testing for STIs (chlamydia, gonorrhoea, trichomoniasis and syphilis) to those 
found to be at increased risk (including persons with multiple sexual partners in the past year, MSM, sex workers 
and persons engaging in transactional sex) (very low level of evidence). However, since transmission may still occur 
within the prison setting, it is also advisable to continue assessing the risk for STIs periodically during incarceration 
and offer STI testing accordingly (very low level of evidence). Client-initiated testing was considered a valid 
approach to complement and enhance these efforts and thus could be continuously promoted during prison stays 
(very low level of evidence).  
ECDC and EMCDDA assessment 
The available evidence suggests that provider-initiated strategies for STIs testing yield a higher uptake than client-
initiated strategies. Provider-initiated testing is also consistent with the general principle of disease prevention to 
not delay diagnosis, in order to offer appropriate treatment, and prevent, as much as possible, complications and 
transmission within prison settings. However, no clear indication on the most effective timing and modality for STIs 
active case finding in prison settings may be derived from the existing evidence. Several approaches may be 
considered, including risk-based, age-based or universal testing for STIs, though evidence of their effectiveness in 
EU/EEA prison settings is very limited (see Sections 5.1.3 and 5.1.7).  
 
4.4 Tuberculosis 
4.4.1 Evidence base 
The evidence base on active case finding for TB in prison setting was composed of twenty-eight relevant 
publications, 11 of which focussed on active TB and 17 on LTBI. Nine of the TB studies were descriptive studies 
that reported mostly on uptake, positivity rates and treatment initiation, and two were cost-effectiveness studies. 
All the included LTBI studies were descriptive, reporting mostly on uptake, positivity rates and treatment initiation. 
The evidence base was derived from a wide range of geographical areas within and beyond the EU/EEA, and 
different testing modalities and testing combinations were reported. Overall, the evidence base was limited and of 
low/very low quality. As a result, it was difficult to issue evidence-based conclusions regarding the most effective 
testing approach for active TB and LTBI in prison settings. Tables 7 and 8 provide an overview of the evidence 
base. Further details are presented in the ECDC/EMCDDA systematic review [62]. 
Table 7. Evidence base on effectiveness of active case finding for TB in prison settings  
Intervention 
description 
 how 
 when 
 who 
Studies included  
[no. of studies, design, reference, 
sample size, no. of studies from 
EU/EEA] 
Outcome 1: Uptake Outcome 2: Positivity 
rate 
Other outcomes Level of 
evidence 
Chlamydia and gonorrhoea 
 
                                                                    
3 The seven principles (7Cs) are: consent, confidentiality, counselling or communication, correct test results, connection to care 
and treatment, supportive culture of the prison system, and continuity of care post-release. See Chapter 5 for an explanation of 
these principles. 
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Intervention 
description 
 how 
 when 
 who 
Studies included  
[no. of studies, design, reference, 
sample size, no. of studies from 
EU/EEA] 
Outcome 1: Uptake Outcome 2: Positivity 
rate 
Other outcomes Level of 
evidence 
 Provider-
initiated 
 At entry 
 Universal 
N=4 studies; 
1 cross-sectional [138], sample size 
[4890] 
1 surveillance (focused on testing 
methods) [139], sample size [NR] 
1 before-after (focused on testing 
methods) [140], sample size 
[62281], follow-up [NA] 
1 unpublished research [141], 
sample size [NR] 
 
EU/EEA (1) 
75%-77.3% (TST) 
 
67.1% (CXR (of TST-
positives)) 
 
100% (CXR) 
11.9%-46.9% TST-
positive; 
0.05-2.3% confirmed TB 
Treatment initiation: 
87.1% 
All very low 
 Provider-
initiated 
 During 
imprisonment 
 Universal 
N=1 study; 
Longitudinal [142]*, sample size 
[NR], follow-up [NR] 
 
EU/EEA (0) 
99.8% 0.4% confirmed TB Treatment initiation: 
100% 
Very low 
 Provider-
initiated 
 At entry and 
during 
imprisonment 
 Universal 
N=2 studies; 
1 longitudinal [143], sample size 
[3081], follow-up [NR] 
1 conference abstract [144], sample 
size [600] 
 
EU/EEA (2) 
82.5% at entry 0.24% at entry, 2.2% 
during imprisonment (1 
study); 0.3% overall (1 
study) 
Treatment initiation: 
100% 
Very low 
 Provider-
initiated 
 At entry and 
during 
imprisonment 
 Universal 
N=1 study; 
Survey [41], sample size [22 
countries] 
 
EU/EEA (1) 
At entry: 94% of responding 
EU/EEA countries, uptake 
ranged from 63% in Latvia 
to 100% in Slovakia and 
Spain 
 
During imprisonment: 56% 
of responding EU/EEA 
countries, uptake ranged 
from 5.5% in Cyprus to 
100% in Malta  
At entry: TB detection 
rates ranged from 41.7 
per 100 000 in Spain to 
1,255 per 100 000 people 
in detention screened in 
Latvia 
 
During imprisonment: TB 
detection rates ranged 
from 0 per 100 000 in 
Cyprus, Malta and 
Romania to 918.5 per 
100 000 screened in 
Latvia 
In the WHO European 
region, prison staff were 
screened annually for TB 
or latent TB infection in 
50% of the countries, 
occasionally in 22.7% 
countries, and not at all 
in 13.6% countries 
Very low 
 Provider-
initiated 
(mandatory) 
 NR 
 Universal 
N=1 study; 
Cross-sectional [145], sample size 
[22920] 
 
EU/EEA (0) 
NR 1.3% TST-positive; 
0.03% confirmed TB 
Treatment initiation: 
100% 
 
Very low 
LTBI 
 Provider-
initiated 
 At entry 
 Universal 
N=5 studies;  
1 longitudinal [146], sample size 
[NR], follow-up [NR] 
1 cross-sectional [147], sample size 
[3081] 
3 conference abstracts 
[67,148,149], sample size [711, 
378, 24101] 
 
EU/EEA (4) 
11.6%-90.2% (TST) 7.2%-50.4% (TST); 
48.3% (TST+IGRA) 
 
at 2nd TST: 11.7%  
NR Very low 
 Provider-
initiated 
 During 
imprisonment 
 Universal 
N=6 studies; 
1 cross-sectional [23]*, sample size 
[3468] 
5 conference abstracts [69,150-
153], sample size [4072, 2871, 
7500, 197, 378] 
 
EU/EEA (6) 
15.4%-100% 
 
15% increase in percentage 
of individuals tested after 
peer educators and 
specialist on communicable 
diseases intervention 
 
31.5% increase in 
acceptance after peer 
educators presentation and 
pamphlets on importance of 
screening 
17.2%- 50.4% NR Very low 
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Intervention 
description 
 how 
 when 
 who 
Studies included  
[no. of studies, design, reference, 
sample size, no. of studies from 
EU/EEA] 
Outcome 1: Uptake Outcome 2: Positivity 
rate 
Other outcomes Level of 
evidence 
 Provider-
initiated 
 At entry and 
during 
imprisonment 
 Universal 
N=3 studies; 
1 longitudinal [143], sample size 
[478], follow-up [NR] 
2 conference abstracts [154,155], 
sample size [158, NR] 
 
EU/EEA (3) 
82.5%-100% (TST) 41.3%-44.9% Treatment initiation: 23% Very low 
 Provider-
initiated 
 At entry 
 Migrants in 
prison 
N=1 study; 
Conference abstract [156], sample 
size [134] 
 
EU/EEA (1) 
100% 49.3% NR NA 
 Provider-
initiated  
 NR 
 Universal 
N=1 study; 
Cross-sectional [157], sample size 
[NR] 
 
EU/EEA (0) 
NR 18% (TST) Treatment initiation: 58% Very low 
 Provider-
initiated 
(mandatory) 
 NR 
 Universal 
N=1 study; 
Cross-sectional [145], sample size 
[22920] 
 
EU/EEA (0) 
NR 0.9% Treatment initiation: 58% Very low 
 Provider-
initiated  
 NR 
 Correctional 
officers 
 
N=1 study; 
Survey [158], sample size [1174] 
 
EU/EEA (0) 
NR NR Testing officers at 
employment start 
occurred in 61.9% of 
responding jails, and 
74.5% tested officers 
after exposure to active 
TB 
 
Of all officers tested, 
0.39% had LTBI test 
conversions, 0.38% 
among jails that test 
once or more a year, and 
0.43% among jails that 
do not test once or more 
a year 
Very low 
 
 
CXR: chest X-ray, IGRA: interferon gamma release assay, LTBI: latent tuberculosis infection, NA: not applicable, NR: not reported, 
PCR: polymerase chain reaction, TB: tuberculosis, TST: tuberculin skin test 
$ Active TB refers to pulmonary TB 
* Used different promotion strategies: informed about TB and its control, reluctant people in prison are encouraged by other 
people in detention/staff [142]; presentation on advantages of testing by peer educators, pamphlets on importance of testing 
[23] 
Table 8. Evidence base on cost-effectiveness of active case finding for TB in prison settings  
Intervention 
description 
 how 
 when 
 who 
Studies included  
[no. of studies, 
perspective, reference, 
time horizon, no. of 
studies from EU/EEA] 
Scenarios Conclusions Level of 
evidence 
Chlamydia and gonorrhoea 
 Provider-
initiated 
 NR 
 Universal 
vs.  
 No active case 
finding 
N=1 study [159], 
perspective [healthcare 
system], time horizon [10 
years] 
 
EU/EEA (1), multicountry  
1. No active case finding 
 
2. MMR screening 
 
3. Symptom screening 
 
4. Sputum PCR screening 
 
5. Combinations of two or all of the 
three screening methods 
Annual screening of the general prison population 
with sputum PCR was the most cost-effective 
method based on incremental cost per QALY. 
Adding sputum PCR to the currently used strategy 
of annual MMR screening was cost-saving 
compared to MMR screening alone, but resulted 
only in minor reductions in (MDR-) TB cases. 
Symptom-based strategies were less effective and 
more expensive than MMR-based strategies.  
Moderate 
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Intervention 
description 
 how 
 when 
 who 
Studies included  
[no. of studies, 
perspective, reference, 
time horizon, no. of 
studies from EU/EEA] 
Scenarios Conclusions Level of 
evidence 
 Provider-
initiated 
 At entry 
 Universal 
N=1 study [160], 
perspective [NR], time 
horizon [NR] 
 
EU/EEA (0), USA (1) 
1. Routine miniature chest 
radiography 
 
2. TST 
 
3. Symptom-based 
Based on analysis of the cost per active TB case 
identified, screening for active TB at entry using 
miniature chest radiography seemed to be more 
sensitive and more cost-effective than screening at 
entry with either TST or based on symptoms. 
Low 
MDR: multi-drug-resistant, MMR: mass miniature radiography, NR: not reported, PCR: polymerase chain reaction, TB: 
tuberculosis, TST: tuberculin skin test 
$ Active TB refers to pulmonary TB 
In addition, four supranational guidelines were identified, providing recommendations for systematic passive and 
active case finding for active TB at prison entry and during incarceration [10,45,161,162]. National guidelines 
specific to prison settings from the United Kingdom and Italy recommended universal screening for active TB at 
prison entry, with one recommending additional annual check-ups for individuals with predisposing conditions [163-
165]. A Dutch guideline recommended active case finding at entry only for high-risk groups and foreign-born 
individuals [166]. Active case finding for LTBI was covered in two national and one supranational guidelines, the 
latter not specific to prison settings [43,163,164]. All documents recommended provider-initiated testing for LTBI 
among high-risk individuals such as people originating from areas with a high prevalence of TB, contacts of active 
TB cases, and individuals at a higher risk of developing active TB (e.g. HIV-positive people). Further details are 
presented in the ECDC/EMCDDA systematic review [62]. 
4.4.2 Ad hoc scientific panel opinion  
Despite the overall low level of evidence, the scientific panel shared the opinion that it is advisable to actively 
promote TB case finding in order to offer appropriate and timely treatment and reduce the risk of transmission and 
of developing disease.  
The available evidence confirms previous reports [4,40] of high TB prevalence in prison settings in the EU/EEA 
(Table 7), and raises concerns about the relative proportion of drug-resistant TB cases [167]. Socioeconomic and 
behavioural factors which are predisposing for active TB development are prevalent among prison populations, and 
high-risk groups for active TB are generally overrepresented in EU/EEA prison settings [5,10]. In closed settings, 
such as prisons, active TB is a potentially highly infectious respiratory disease that can spread easily in 
overcrowded and poorly ventilated environments, as corroborated by existing incidence data and data on the 
relative risk for active TB in prison settings [40,143]. Prevention of TB transmission in prison settings is of 
paramount importance, both at the individual and the public health level, and provides a compelling argument for 
case finding for active TB in prison settings.  
The available evidence suggests a high prevalence of LTBI among people in prison in the EU/EEA (Table 7), 
particularly among individuals originating from high-prevalence countries and underserved communities, though 
with some degree of heterogeneity between studies [148,152-156]. Although LTBI is not contagious and does not 
pose a direct threat to people in prison, it may progress to infectious active TB. Risk of LTBI re-activation is higher 
in immunocompromised people (e.g. HIV-positive people) and may be increased by other factors common in 
people in prison (e.g. poor nutrition, stress, drug use) [5]. LTBI treatment is effective against re-activation of TB. 
According to one included study, the relative risk of developing active TB while in prison was significantly higher for 
LTBI-positive individuals refusing treatment [143]. However, the rationale for LTBI active case-finding is tempered 
by other relevant factors such as the underlying TB prevalence and coverage of BCG vaccination in the general 
population, the population characteristics of the target prison population (e.g. proportion of individuals from 
endemic countries) and the available resources. 
Although it was not possible to determine the ideal timing and modality of testing for TB in prison settings based 
on the available evidence, the scientific panel reached a consensus on active case finding for active TB and LTBI, 
provided that seven principles (7Cs4) are guaranteed. It was considered important to offer provider-initiated testing 
for active TB within 48 hours of prison admission (very low level of evidence). It was also considered beneficial to 
implement regular provider-initiated active TB testing among individuals at high risk of TB infection or LTBI 
reactivation (e.g. people living with HIV) (very low level of evidence). To complement these efforts, passive case 
finding was considered a valid approach to increase case detection during incarceration (very low level of 
evidence). Screening for active TB could also be considered for staff newly employed to work in prison setting. 
 
                                                                    
4 The 7Cs are: consent, confidentiality, counselling or communication, correct test results, connection to care and treatment, 
supportive culture of the prison system, and continuity of care post-release. See Chapter 5 for an explanation of these principles. 
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Repeated screening (e.g. yearly) could be considered, depending on national/local epidemiology and available 
resources.  
LTBI screening followed by an offer for appropriate treatment could also be considered, depending on 
national/local epidemiology (e.g. low-incidence countries) and available resources (very low level of evidence). 
Regular provider-initiated LTBI screening could be considered for high-risk individuals (e.g. people living with HIV) 
(very low level of evidence). Screening for LTBI could be considered for newly employed prison staff (very low level 
of evidence). 
ECDC and EMCCDA assessment 
Based on the available evidence on TB active case finding in prison settings, and considering the public health 
implications of TB transmission in closed settings, it is advisable to offer universal provider-initiated testing at 
prison entry. Provider-initiated testing at prison entry is also consistent with the general principle of disease 
prevention to not delay diagnosis, in order to offer appropriate treatment and prevent, as much as possible, further 
transmission within the prison setting (see Section 5.1.8).  
LTBI provider-initiate testing could also be considered, at least for individuals at high risk of disease progression, 
depending on local epidemiology and availability of resources (see Section 5.1.8). 
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5 Implications for public health practice and 
research 
5.1 Public health practice 
This section presents specific considerations related to the implementation of active case finding initiatives in prison 
settings. It encompasses a number of various issues, ranging from human rights aspects to testing modalities and 
disease-specific considerations. This section is intended to complement Chapter 4 by providing evidence-based and 
practice-based information to support the design and planning of active case finding initiatives in prison settings in 
the EU/EEA. 
5.1.1 Equivalence of care and human rights considerations 
A large number of guidance documents defines the principles and standards of prison healthcare delivery [10,46-
51]. One of these principles maintains that people in prison have the same right to care as those in the community. 
This so-called ‘principle of equivalence of care’ is an internationally agreed minimum [48,49,60]. It aims to secure, 
as much as possible, the same standards of healthcare for people in and outside of prison. However, based on the 
principle of equitable care or equivalence of health objectives, people in prison are entitled to expect services and 
interventions over and above those that are available in the community: this is due to the higher burden of, for 
example, viral hepatitis, HIV and TB and the increased responsibility of the state, which is based on human rights 
obligations [57,58]. Failure to detect or properly treat a health problem or adequately assess treatment needs, may 
raise human rights issues, as do malpractice, negligence or errors in medical treatment [51,168]. The combination 
of measures and recommendations set forth by applicable national and international guidelines, alongside 
normative provisions, constitute a set of standards that can serve as an indicator of compliance with human rights 
requirements. 
In practice, an approach to communicable diseases that is also sensitive to human rights should translate into 
proactive engagement of healthcare staff, early disease detection, awareness and application of medical standards 
and ethics, prevention and vaccination, and treatment [51]. As in other settings, early detection allows for 
preventive measures. In the context of highly infectious airborne diseases (such as TB), isolating a patient during 
the infectious period might be justified, as this would be in accordance with medical standards and guidance [53]. 
By contrast, medically unjustified segregation of imprisoned people who suffer from certain conditions (e.g. HIV) 
would violate human dignity or be considered degrading and discriminatory.  
Equivalence of prevention, treatment, care, and support can best be achieved by ensuring continuity and 
coordination of care between community and prison services, and would also avoid the duplication of efforts. In 
some countries, the responsibilities for healthcare in prison settings and healthcare in the community lie with 
separate government departments/health authorities. If this is the case, a joint strategic approach to promote 
continuity and coordination of care between community and prison services is advisable. 
5.1.2 7C principles 
The active case finding process in prison settings poses a number of specific challenges. Most people held in 
prison, especially at the early stages of their incarceration, are in a state of considerable fragility and vulnerability, 
at times combined with aggressiveness and distrust; the reasons for this are complex, but can include general 
psychological problems, substance use, poor health, educational deficits, and poor social skills. It is advisable to 
take these aspects into consideration during the planning and implementation of active case finding initiatives in 
prison settings. In this context, WHO formulated five principles and called them the ‘five Cs’: consent, 
confidentiality, counselling (or communication), correct test results, and connection to prevention, care, and 
treatment [114].  
These principles should constitute the foundation of active case finding, both in prison settings and the community. 
With regard to the prison system, the ad hoc scientific panel endorsed two additional principles as particularly 
relevant: continuity of care post-release and an overall supportive culture within the prison system.  
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Figure 2. The seven Cs 
 
In accordance with recognised international standards [53,54,114], active case finding should be voluntary and 
based on informed consent. People who get tested, including people in prison, would need to be informed about 
the testing procedures and their right to decline testing. Regardless of whether the offered interventions are opt-in 
or opt-out, seeking consent for testing would need to take into account that people in prison often feel vulnerable 
and disempowered. This is often aggravated by language problems, developmental and educational deficits, and 
poor social skills [51,53]. It is therefore advisable to train staff members (e.g. physicians, nurses), support staff 
(e.g. from non-governmental organisations) or peers in counselling. Legal parameters for consent may differ 
between countries; national requirements should be taken into account when designing testing programmes. 
In accordance with international standards, every person undergoing testing should receive his/her results as soon 
as possible, and, if tested positive, receive appropriate care and treatment. If tested negative, preventive care 
should be offered, for example HBV vaccination. Active case finding alone is insufficient if not followed up by 
appropriate control and prevention measures. Given the transitory nature of incarceration, continuity of care post-
release is essential to reap the rewards of testing interventions in prison settings. 
A supportive culture is crucial to the success of prevention and control interventions. Trust and confidence in the 
prison healthcare services should be encouraged, not only among people in detention but also among prison staff, 
especially correctional officers. Health promotion, peer-education, training and information sessions for staff and 
people held in prison may be considered (see Section 5.1.3). 
A high level of healthcare services, as envisioned by the 7 Cs, can be attained if staff members work together and 
focus on common goals, for example by providing continuous feedback and sharing intervention outcomes related 
to the virtuous circle of the quality improvement process5. 
Skilled and motivated healthcare workers in sufficient numbers are necessary to respond to health needs in 
prisons; shortage of skilled clinical staff is a common problem in prison settings [51,53]. 
5.1.3 Active case finding modalities 
There are several modalities in which testing can be offered. While mandatory testing is one of those, it will not be 
considered in this guidance document because it runs contrary to the principle of informed consent. Mandatory 
testing in prison settings will rarely meet medical ethics and human rights requirements as it constitutes an 
interference with the right to private life and would fail to meet the requirements of the European Convention on 
Human Rights and the tests developed by the European Court of Human Rights. 
 
                                                                    
5 The EU-funded project ‘Joint action on improving quality in HIV prevention’ (quality action) developed a basket of practical tools 
and materials to maximise the quality of HIV prevention projects and programmes. More information is available from: 
http://www.qualityaction.eu/choosetool.php  
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Voluntary testing may be initiated by the healthcare provider (provider-initiated testing), i.e. by offering tests for 
communicable diseases to people held in prison; testing can also be requested by people in prison, especially by 
people with symptoms and people who perceive a risk of infection (client-initiated testing). Voluntary provider-
initiated testing can be offered in two modalities: 1) opt-in, where testing is offered to all eligible individuals (often 
upon identification of risk factors), who then choose whether to have the test, and 2) opt-out, where all consenting 
eligible individuals are informed that a test will be conducted, unless the person actively refuses. Due to differences 
in the perception of opt-in and opt-out in different countries and settings, this document uses the term ‘provider-
initiated’ because it covers opt-in and opt-out approaches. 
The patient’s consent to screening and testing is required, regardless of the type of testing service provided in a 
prison setting; this consent is grounded in the fundamental right to private life (see Section 5.1.2). While both opt-
in and opt-out approaches adhere to the principle of consent prior to testing, the implementation of opt-out testing 
in prison settings may raise concerns over possible coercion or intimidation on the part of the service providers. 
People in detention may lack self-determination and may fail to reject testing because they may not fully 
understand their right to refuse, and that their refusal will be without negative consequences [169]. Opt-out 
testing, especially if well-designed and thoroughly explained, can be consistent with the obligation of the state to 
uphold a person’s right to the highest standards of health and healthcare. Opt-out approaches have been shown to 
result in higher uptake rates and in improved testing coverage in the prison population [1,61,123].  
Opt-in approaches failing to achieve a sufficient level of coverage will also fail to adequately prevent further disease 
transmission within prison settings [61,74,91]. With regard to human rights, the state’s responsibility to uphold 
human rights is ensured as long as opt-in testing does not result in undertesting.  
Opt-out testing might be a more favourable option as it is less subject to stigma and discrimination, but some 
Member States may lack the legal framework for opt-out testing.  
The optimal timing for active case finding initiatives was scarcely researched in the reviewed literature. However, it 
is evident that active case finding as soon as possible after prison entry is essential to prevent further disease 
transmission in the prison population as well as to offer adequate care to diagnosed people, including 
initiation/continuation of treatment. A medical examination upon admission [49] may offer a good opportunity for 
testing. However, the emotional and psychological status of individuals entering detention needs to be taken into 
full consideration. Active case finding does not necessarily have to be conducted at entry but can also take place in 
the days following admission (i.e. within seven days), ideally after the so-called ‘entry trauma’ [170,171] – with the 
notable exception of active TB testing. Early detection may also help dispel claims that infection took place after 
admission, or serve to allocate or apportion responsibility. Although the individual and public health benefits of 
active case finding are greater if entry testing is performed, additional testing opportunities, either provider- or 
client-initiated, could be considered. This includes targeting high-risk groups, testing those who refused testing at 
prison entry, testing people who were involved in exposure incidents, or testing people affected by an outbreak.  
Several initiatives tried to increase testing uptake in prison settings, but the level of corresponding evidence is 
generally low or very low. Measures included health promotion and peer-led education interventions targeted at 
people in detention. A combination of different approaches was reported, encompassing enhanced pre-test 
counselling, handing out information materials (e.g. leaflets, personalised information letters), education sessions 
on communicable diseases and the advantages of testing, and peer-led education or support programmes 
[23,98,103,172]. While a significant change in testing uptake was reported by only one study [103], increases 
were observed in all. Two studies reported that educating prison healthcare staff on communicable diseases and 
the benefits of active case finding may increase participation and acceptance rates [80,102]. 
Focus on implementation 
The role of peer educators in prison settings: the Italian FLEW project   
The FLEW project (Free to live well with HIV in prison) is the result of a consolidated effort between NPS Italia 
Onlus (a network of people living with HIV), SIMSPe (the Italian Society for Prison Health and Medicine) and the 
University Ca' Foscari Venice. In 2016, 677 people in prison, 107 prison officers, 112 healthcare professionals, 
70 educators and office staff, and 28 volunteers were given a questionnaire to assess their knowledge on HIV and 
HIV transmission. They were also asked to report on the level of stigma attached to HIV among people in prison, 
prison officers, educators and healthcare professionals.  
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For example, almost 60% of those interviewed thought that engaging in a fistfight – which can easily lead to 
bleeding – would not expose them to the risk of HIV transmission.  
In 10 prisons across seven Italian regions, educational activities were organised for people in detention, prison 
officers and educators. A group of peer educators – people living with HIV (PLHIV) who also at some point in their 
lives were imprisoned – conducted a number of activities aimed at people in detention. Their work was essential to 
meet the project goals of improving HIV prevention in prisons, fighting stigma, and improving the quality of life of 
PLHIV. Another innovative element was the introduction of HIV rapid testing in prison settings. Over 650 tests were 
requested, both by people in detention and prison staff. All appreciated the testing opportunities presented by the 
project. The methods developed in this project are adaptable to other detention facilities.  
Additional information is available from: http://www.npsitalia.net 
 
As suggested by the retrieved evidence, diagnostic methods may influence acceptability and uptake of testing 
services among people in prison. The choice of a diagnostic method for a given communicable disease depends on 
a broad spectrum of factors, such as test characteristics, national and/or European regulations, available facilities 
and resources at national and local levels, and the specific characteristics of the people in prison.  
It is important to note that invasive methods and/or diagnostics relying exclusively on venous blood may 
discourage uptake [61,66]. Higher acceptance/uptake of testing services was reported when oral tests or dry blood 
spots were used to complement routine venipuncture [79,80,97]. Acceptance was also higher after the introduction 
of rapid diagnostic tools for TB (e.g. chest X-ray [139,140]. The latter produced an increase in the rate of active TB 
diagnosis and shortened the time to isolate TB cases.  
5.1.4 Prison settings 
Prisons and custodial institutions differ from other settings in a number of ways when it comes to healthcare 
delivery. Structural barriers, such as lack of adequate health facilities, limited resources, high turnover of the prison 
population (average detention period in Europe is seven months [3]) [77,78] are coupled with individual barriers 
such as lack of trust in prison institutions, concern about confidentiality in prison settings, and difficult living 
conditions [75,95,173,174].  
Testing coverage in prison is likely to be influenced by structural and organisational challenges, including the 
availability of adequate resources, which can affect the delivery of healthcare services. According to the available 
evidence, the most relevant barrier to testing uptake, performance and result notification (including induration 
reading for TB testing) was the transfer or sudden release from detention facilities [62]. This is probably more 
relevant for jails or remand prisons, where individuals are generally incarcerated for shorter periods of time. 
Differences may also be connected to the specific situation in a country or national prison system.  
In addition, prison settings may differ from each other in the demographics of the incarcerated population 
(nationalities, minorities, etc.). These differences may have implications for the specific needs of the various prison 
population groups and need to be taken into consideration, alongside local availability of healthcare and diagnostic 
services, when planning and implementing active case finding initiatives.  
Prison staff may also influence the implementation of prevention measures and other healthcare interventions in 
prison settings. Apart from the well-recognised need for dedicated training for healthcare staff [10], education 
interventions targeting correctional officers may increase cooperation between different groups, create awareness 
about the right to health, and ultimately ensure the successful implementation of healthcare interventions. 
Special attention should be paid to all factors that contribute to disease transmission in prison settings. Poor 
hygiene, overcrowding, lack of availability of (and access to) evidence-based prevention tools, and under-resourced 
healthcare services can undermine the right to health of people in prison and thus promote disease transmission 
[10]. Active case finding cannot curb communicable disease spread in prison settings if implemented in isolation 
and without properly addressing adverse circumstances and structural barriers. 
5.1.5 Other people in prison settings 
People ‘in prison’ not only include people in detention, but also visitors, support and service providers from the 
community, and staff. All are exposed to a higher risk of acquiring communicable diseases while visiting or working 
in prison. People who enter the prison environment can also be an inadvertent source of infection for the prison 
population, for instance during a seasonal influenza wave.  
It is important to pay close attention to the fundamental right to health of people working in prisons or visiting 
prisons, especially prison staff, and consider the implications this has for employment under national labour law. 
Such considerations are particularly important when prison staff are called upon to work in places with poor 
hygiene, squalid material conditions, poor working environments, prison overcrowding. Equally relevant are 
conditions characterised by a high prevalence of mental problems, physical illness, or infectious disease [175]. It 
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would be beneficial for prison staff to be able to take informed decisions which protect their safety and health, in 
addition to adequate occupational health services [176]. Prison staff should also be seen as a potential target 
group for active case finding initiatives at the start of employment and at regular intervals thereafter. 
5.1.6 Blood-borne viruses  
The existing body of evidence provides a clear indication of an elevated prevalence of blood-borne virus (BBV) 
infections in the prison population [4,86]. This is the result of the combination of high disease prevalence among 
people entering a prison setting [62] and the high risk of disease transmission in prison settings due to high-risk 
behaviours among people held in prison [177]. High-risk behaviours for BBV transmission inside prison settings 
include: unprotected sexual relations, injection of drugs without sterile needles and syringes, sharing of drug use 
paraphernalia, tattooing, body piercing, scarifications, blood brother/sister rituals, unsafe medical equipment 
(dental, medical, gynaecological), and sharing of other equipment (spoons, razors, toothbrushes). These 
behaviours are among the principal drivers of the HIV and viral hepatitis epidemics, and people in prison engaging 
in these high-risk behaviours are a key vulnerable population.  
For active case finding to be effective in preventing BBVs transmission in prison settings, it is advisable to offer a 
comprehensive package of prevention services (e.g. health promotion, provision of sterile injecting equipment, 
opioid substitution treatment and other effective treatment of drug dependence, provision of condoms, safe 
medical procedures), combined with psychological and social services [16,178]. These interventions and their 
modalities of implementation in prison settings are explored in a dedicated guidance module (see Figure 1). 
Several studies refer to the implementation of targeted active case finding for high-risk groups within the prison 
population, most commonly HCV testing for PWID and people living with HIV [74,78,179]. A number of studies 
analysed alternative scenarios of targeted HCV testing for PWID, including the cost-effectiveness of a variety of risk 
assessment approaches (Table 3) [80-85]. Targeted HCV testing is shown to capture only a limited fraction of HCV 
cases [74] and does not succeed to accomplish the health benefits, neither for the individual patient nor for the 
community, of other approaches [85]. Valid arguments in favour of universal active case findings for BBVs in prison 
settings are: concerns that risk-based testing is insufficient; the need to reduce the number of undiagnosed cases 
of HIV and chronic viral hepatitis; and the availability of effective prevention and control measures. Regular or 
continuous testing during incarceration could also be considered, either client-initiated or targeted at high-risk 
groups, ideally in settings where the prevalence of BBV infections is high [96]. In addition, international [180] and 
national guidelines on antenatal screening for HBV and HIV should also be applied to people in prison. 
Focus on implementation: universal screening for BBVs at admission 
into prison – Pathfinder Programme in the United Kingdom 
Since 2014, Public Health England (PHE) Health and Justice has been supporting HM Prison & Probation Service 
(previously the National Offender Management Service) and National Health Services (NHS) England in the delivery 
of opt-out testing for blood-borne viruses (BBV) in all adult prisons in England. The evaluation of phase two 
Pathfinder prisons was published by PHE Health and Justice in October 2016, with phase three evaluation slated for 
publication in Q4 of the 2017/18 financial year [1,2].  
Roughly 70% of the prison estate in England was implementing BBV opt-out testing as of Q4 2016/17, with full 
implementation expected by the end of the 2017/18 financial year. Performance in relation to BBV opt-out testing 
programmes is measured by NHS England through the collection of data via the Health & Justice Indicators of 
Performance (HJIPs). These metrics include specific reports of offer and uptake of HIV, hepatitis B and hepatitis C 
testing within 72 hours of reception to prison as well as referral for treatment for those found infected. These data 
show that in England in 2016/17, 16 321 tests were conducted for hepatitis B infection, 21 268 for hepatitis C 
infection and 37 474 for HIV infection. The proportion of new receptions receiving tests for HCV increased from 
5.3% in 2010/2011 to 11.5% in 2015/2016 [2].  
Additional information and supporting documents on The Pathfinder Programme and on BBV opt-out testing are 
available here: https://www.gov.uk/government/publications/improving-testing-rates-for-blood-borne-viruses-in-
prisons-and-other-secure-settings 
 
Implementation of active case finding is generally considered to be justified when an effective prevention or control 
measure exists and is made available to a person individual after the receipt of test results. While effective 
measures exist for each BBVs infection, ensuring access in prison settings may be challenging. Highly effective 
treatment for hepatitis C is largely available (direct acting antivirals, DAAs) in the EU/EEA, but the differences in 
accessibility between countries remain large. Testing interventions for hepatitis C in prison settings may be limited 
to specific population groups if the availability and affordability of DAAs cannot be ensured. On the other hand, 
implementation of active case finding for hepatitis C may result in a better understanding of the size of the 
population in need of treatment in prison settings, leading to more accurate planning and resource allocation. 
Public health guidance on active case finding of communicable diseases in prison settings  SCIENTIFIC ADVICE 
30 
Although there is no cure for HIV and chronic hepatitis B, existing treatment options are effective in halting disease 
progression and reducing transmission. In addition, effective vaccination for HBV is an additional preventive 
measure that may be offered to unexposed and unvaccinated individuals. Finally, from a human rights perspective, 
not actively promoting active case finding for BBVs may be interpreted as depriving people in detention of the 
possibility to receive effective treatment for HIV and chronic hepatitis B or be cured from chronic hepatitis C. 
One point of concern regarding active case finding for HIV is that a positive result may lead to unjustified 
segregation and discrimination of HIV-positive patients in certain prison institutions. Only full compliance with the 
7C principles (Section 5.1.2) by the national prison system and its detention facilities can guarantee the rights of 
the individual detainee while at the same time maximising the prevention potential of active case finding initiatives.  
5.1.7 Sexually transmitted infections  
STIs are often asymptomatic. As a result, symptom-driven case finding may be insufficient because asymptomatic 
people may not be aware of an infection [125-127]. Raising awareness about STIs, prevention measures, 
symptoms, and the availability of testing services for people in detention is important to increase the number of 
STI diagnoses and improve disease control in prison settings. Health promotion initiatives which target people in 
detention are more effective when implemented at entry or immediately after incarceration due to the increased 
risk of sexual violence in the early days of detention. In addition, peer support may be relevant to promote 
awareness among people in prison [23,98].  
Active case finding for STIs can lead to a higher disease detection rate in the prison population [124-127,131]. 
Active case finding for syphilis was generally offered to all people entering a prison setting [98,129,181] or during 
imprisonment [23,172]. Active case finding for chlamydia and gonorrhoea (usually combined) and trichomoniasis 
was frequently targeted at specific population groups based on sex [118,120,125,126] or age [122,127]. While 
sexual risk behaviours for STIs are well known (e.g. multiple sexual partners, sex between men), the sensitivity of 
behaviour-based risk assessment approaches to evaluate the likelihood of syphilis, chlamydia, gonorrhoea and 
other STIs may be affected by the challenges of a full disclosure. Other more easily measurable criteria (e.g. age, 
sex, existing co-infections), as recommended by several international guidelines, may be considered instead 
[36,135-137]. Epidemiological data on the underlying prevalence/incidence of STIs in the community and the 
availability of resources (including laboratory facilities and appropriate treatment) may be considered when 
assessing or planning active case finding initiatives for STIs. Finally, not only urogenital, but also rectal (and 
possibly pharyngeal) infections could be considered for testing, in line with reported sexual practices. In addition, it 
is also advisable that international [180,182] and national guidelines on antenatal screening for syphilis are applied 
to people in prison.  
Sexual activities in prison settings may be illegal, but their occurrence cannot be completely prevented. This 
justifies the continuous re-assessment of the risk for STIs and the assessment of testing needs during 
incarceration, e.g. after a prison furlough or conjugal visits. It is important to note that the detection of an STI may 
constitute proof of illegal behaviour and lead to sanctions. It is advised that medical information is therefore 
treated confidentially, but when healthcare providers detect coercive sex activity, they may have the duty to report 
it. Rape and sexual aggression among people in prison and between prison staff and people in prison has received 
little attention, despite reports from many prison systems in many countries [10]. 
Finally, notification of partners of incarcerated individuals diagnosed with an STI is advisable (after patient’s 
consent). It is advisable that partner notification procedures follow existing national guidance for the general 
population.  
5.1.8 Tuberculosis  
Since active pulmonary TB is highly infectious, screening people at prison admission is advisable so that prevention 
and control measures (e.g. treatment, isolation) can be taken to avoid onward transmission [183]. When planning 
active case finding initiatives for TB in prison settings, it is important to take into consideration the different 
epidemiological situation of TB across the EU/EEA [40], the characteristics of the prison population, and existing 
national/international guidelines and national legislation. Certain population groups, which tend to be 
overrepresented in prison settings, are at higher risk for TB and LTBI. These may include foreign-born people from 
high-burden countries, homeless people, and people with substance use disorders. WHO has released a 
compendium of good practices for the prevention and control of (multidrug-resistant) TB in prison, which includes 
models for TB active case finding at prison entry from a number of EU/EEA countries [184]. 
When assessing the need for active case finding for LTBI, the size of the foreign-born prison population from high-
endemic countries is of great relevance, given the high prevalence of LTBI among this group [167,185-187]. The 
relative proportion of LTBI and active TB cases among foreign-born members of the prison population in the 
EU/EEA is related to the underlying dynamics of the overall migrant population. Given the substantial east-west 
gradient of TB endemicity within the EU/EEA [40], internal migration may contribute to the TB burden in the 
migrant population as much as migration from countries outside the EU/EEA. In recent years, the influx of foreign-
SCIENTIFIC ADVICE Public health guidance on active case finding of communicable diseases in prison settings 
31 
born people has possibly influenced the demographics of the migrant population, which seems to have shifted from 
‘generally healthy’ (economic migrants) to a higher proportion of refugees/asylum seekers in poor health. Many of 
these people come from and/or travelled through countries with a high TB prevalence and are more prone to have 
LTBI and develop active TB.  
The rationale behind active case finding for LTBI varies greatly from country to country, usually because of different 
LTBI prevalence in the community and the (un-)availability of resources. For instance, countries with a high LTBI 
prevalence would not benefit much from screening the prison population for LTBI, while in a country with a low 
burden of TB and a low LTBI prevalence in the general population, LTBI active case finding in the prison population 
might be justified [164,188]. Moreover, in a prison population largely composed of young and immunocompetent 
individuals, the probability of progression to active TB is low, despite the high risk of acquiring LTBI if exposed to a 
smear-positive TB patient. In addition, availability and uptake of LTBI preventive treatment should be considered. 
Evidence suggests that while treatment initiation for active TB in prison settings is generally around 100% 
[142,144,145,167], it is much lower for LTBI [143,145,157,189]. 
Finally, TB active case finding for prison staff may be considered because of the occupational risk and to prevent 
additional sources of infection [176]. According to a survey on TB prevention and control practices in European 
prisons [41], half of the respondent countries reported that they screen annually for TB/LTBI among prison staff. 
Implementation might differ between countries due different or lacking screening protocols and different 
responsibilities: depending on the country, the occupational health of prison staff may fall, for example, under the 
responsibility of the ministry of justice, the interior ministry or the ministry of health. 
The choice of a testing method depends on epidemiological considerations and available resources, including 
laboratory facilities (at national and local levels) and national and international guidelines [161,190]. For first-line 
screening, less invasive methods are generally preferred [139,140]. Risk-based or questionnaire-based screening 
tools are not sufficiently sensitive and should therefore not be the only method for TB active case finding 
[139,167]. CXR is commonly used in the algorithm of active TB diagnosis. In Berlin, Germany, for example, 
screening at intake to prison is performed with mobile digital CXR units if available [167]. Sputum tests are easily 
implemented because individuals can self-collect the specimens under a nurse’s supervision and deliver them to the 
healthcare staff, provided that skilled staff, dedicated equipment, and adequate facilities for sputum collection are 
available. Rapid tests offer clear advantages as they do not require an advanced laboratory, provide rapid results, 
and speed up isolation and treatment initiation. Some rapid tests (e.g. Xpert MTB/RIF assay) also provide 
information on drug resistance.  
If testing for TB infection is considered, either to detect LTBI or as part of the algorithm for active TB diagnosis, 
either a tuberculin skin test (TST) or an interferon gamma release assay (IGRA) can be used. Both tests have 
similar test characteristics [190,191]. Although the use of IGRA is recommended in some EU/EAA countries [164], 
TST is commonly used because it is less resource-intensive. The successful implementation of TSTs is hampered 
by, for example, the need for a second consultation with skilled healthcare staff to read the induration. According 
to the body of evidence, transfer or release from prison settings is the leading cause of incomplete screening for 
LTBI and TB when using the TST, in addition to structural and organisational challenges affecting healthcare 
delivery in prison settings, such as the availability of adequate resources. A previous BCG vaccination may cause a 
false positive reaction to the TST test [190]. BCG vaccination policies differ between EU/EEA countries; while in 
Western Europe only risk groups are vaccinated, some Eastern European countries offer universal childhood 
vaccination. In addition co-infection with HIV may influence TST results so that the underlying HIV prevalence 
should be taken into account [190]. 
5.1.9 Other diseases  
Evidence on active case finding for additional communicable diseases was not retrieved. However, provider-initiated 
testing may be a valid approach to increase diagnosis rates for other communicable diseases at different points in 
time during detention. 
Parasitic diseases or outbreak-prone diseases may warrant active case finding if there are local outbreaks or case 
clusters (e.g. measles, hepatitis A), especially when appropriate prevention and control measures are available 
(e.g. isolation, vaccination, treatment). 
5.1.10 Monitoring healthcare services in prison  
Prison health is an essential part of public health and it would be advisable that prison health is integrated into 
national monitoring systems, which is rarely the case in EU/EEA countries. It is essential to actively monitor all 
elements of healthcare provision in prisons by using standardised data collection tools because only monitoring 
makes it possible to assess the effectiveness of interventions, identify existing barriers, and inform planning and 
resource allocation. Collecting standardised data with a breakdown by risk group would be particularly helpful, 
especially with a focus on people with drug use disorders and drug use patterns (before, during, after prison). For 
example, it would be particularly helpful to collect data on the number of new diagnoses that were reported to 
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national communicable disease surveillance schemes after active case finding interventions in prison settings. This 
would not only allow for a comprehensive assessment of the individual and public health benefits of these 
interventions, but also contribute to a better understanding of the burden of disease in the prison population and 
the related health needs of this population, which, in turn, would provide the basis for adequate resource 
allocation. 
Ideally, an effective disease monitoring system for prison systems should generate reliable data, which could also 
be shared with stakeholders. These data could provide critical evidence when developing tailored interventions for 
prison settings and support the timely and effective resolution of service delivery challenges.  
Ultimately, epidemiological and programmatic data from the prison system should be integrated with 
national/international data collection systems in order to inform comprehensive health policy and planning. The 
WHO Regional Office for Europe, as part of the Health in Prison Project (HIPP), began collecting data for a 
minimum public health dataset for prison health in October 2016. HIPP wants to establish a monitoring framework 
that regularly collects data on the main areas of prison health, including prison health systems (such as financing 
and governance); the prison environment; risk factors for diseases; and the screening, prevention, treatment and 
prevalence of communicable and non-communicable diseases. The data are stored in the Health in Prison 
European Database (HIPED) and are available on the WHO Global Health Observatory. 
5.2 Research 
5.2.1 Challenges of research in prison settings 
Prison settings are probably one of the most challenging environments for conducting scientific research, given the 
ethical implications and the complexity of the prison population. People living in prison often belong to one or 
multiple vulnerable groups, such as migrants, PWID, homeless people, socially marginalised and uneducated 
people. In addition, there is a high prevalence of mental disorders. This heterogeneity, combined with mistrust 
towards prison institutions and the inherently problematic doctor–patient relationship in prisons, makes it difficult 
for people in prison to give an informed consent to participate in health interventions and research initiatives. 
People in prison are generally considered a population that is ‘hard to reach’ and ‘hard to treat’. 
The high turnover of the prison population negatively impacts the participants’ retention and hampers the capacity 
to measure the outcomes of scientific research in prison facilities. This is particularly challenging for the conduct of 
interventional studies, since longitudinal data are difficult to collect. 
Research is further hampered by suboptimal cooperation between prison personnel of different professions and 
roles, shortage of staff trained in conducting research, the lack of economic resources devoted to prison health 
management, and a lack of interest in the institutions responsible for prison healthcare. Research targeting prison 
populations has the potential to expose service gaps, indicate risk behaviours, and point toward unlawful practices 
in prison settings, thus raising issues that some of the responsible authorities may be reluctant to address. 
The lack of public interest in the ‘world behind the walls’ is probably another important reason for the relatively low 
amount of studies conducted in this setting.  
5.2.2 Research gaps and future research 
While this guidance focuses on the EU/EEA, a sizable portion of the evidence was derived from studies conducted 
in the USA. Due to the differences in terms of healthcare systems, correctional systems, and population 
demographics, findings are not always applicable to EU/EEA settings. Moreover, there is a large heterogeneity 
between studies, both in the peer-reviewed and the grey literature, and the general lack of comparative studies 
makes it difficult to compare data and results. Overall, the level of evidence of the included peer-reviewed 
literature studies is quite low. Studies of higher quality and with conclusive evidence are needed as a basis for 
guidance development.  
Operational research on active case findings in prison settings could provide practical and operational insights into 
the implementation of such interventions. In particular, topics such as timing of testing offer, reiteration and 
appropriate time intervals, interventions to increase testing uptake, and risk-assessment criteria for STI and LTBI 
testing are scarcely researched. Long-term follow-up data are needed to assess the benefits of active case finding 
in terms of treatment uptake, adherence to/completion of treatment, cure rates (TB, HCV), and reactivation rates 
following treatment (LTBI). 
In order to fill the knowledge gaps on interventions such as active case finding in prison settings, future research, 
conducted in the EU/EEA, is needed to provide evidence on the feasibility, (cost-)effectiveness, and impact of such 
interventions in the EU/EEA. Studies should have a comparative study design and focus on population and test 
characteristics, health interventions, and intervention outcomes, based on sample sizes that are large enough to 
detect and measure relevant effects.  
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The Worldwide Prison Health Research & Engagement Network (WEPHREN; https://wephren.tghn.org), an open 
access collaborative forum on the health of people in prison, tries to catalyse research activities that focus on 
prison settings through the development of an evidence base and capacity building measures. 
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6 Next steps 
This guidance will be reviewed five years after publication to determine whether all or part of it should be updated 
due to new evidence or new developments in EU/EEA Member States.  
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